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     The adaptive immune response consists of a variety of cells and molecules, among which 
lymphocytes and immunoglobulins (Igs) are the key elements in antigen recognition and 
responses. There are two types of lymphocytes, T cells and B cells. T cells play a pivotal role 
in regulating the immune response and are also responsible for cellular immunity, while B 
cells are essential in the effector phase of humoral immunity. After exposure to antigen and 
mostly with the help of T cells, B cells can differentiate into plasma cells which synthesize 
antibodies or immunoglobulins that can react with antigen. 
     Immunoglobulins are a group of closely related glycoproteins composed of 82-96% 
protein and 4-18% carbohydrate. The basic Ig molecule has a four-chain structure, comprising 
two identical heavy (H) chains and two identical light (L) chains, linked together by inter-
chain disulfide bonds (Fig.1). Intra-chain disulfide bonds are responsible for the formation of 
loops, leading to the compact, domain-like structure of the molecule. The amino terminal 
portions of the H and L chains, characterized by a highly variable amino acid composition, are 
referred to a VH and VL, respectively. The constant part of the L chain is designated as CL, 
while that the H chain are further divided into three distinct subunits: CH1, CH2 and CH3 
(Fig.1). Functionally, the V-regions are involved in antigen binding. The C regions interact to 









Figure 1. Schematic drawing of the basic structure of the human immunoglobulin 
molecule. The amino terminal end is characterized by sequence variability (V) in both H and 
L chains, referred to as the VH and VL regions respectively. The rest of the molecule has a 
relatively constant structure. The C portion of the L chain is termed the CL region or domain. 
The constant portion of the H chain is further divided into three structurally discrete regions: 
CH1, CH2 and CH3. The hinge region is a segment of the H chain, located between the CH1 
and CH2 domains. Fab: Fragment antigen binding; Fc: Fragment crystallisable. The antibody 




         The immunoglobulin G (IgG), a major effector molecule of the humoral immune 
response in man accounts for about 75% of the total Igs in the plasma of healthy individuals. 
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properties and functions, constitute the other 25% of the Igs.  
        Antibodies of the IgG class express their predominant activity during a secondary 
antibody response. Thus, the appearance of the specific IgG antibodies generally corresponds 
with the maturation of the antibody response, which is switched on upon repeated contact 
with antigen. In comparison to antibodies of the IgM class, IgG antibodies have a relatively 
high affinity and persist in the circulation for a longe time. The five classes of human Igs can 
be distinguished on the basis of amino acid composition. This is also the basis for antigenic 
differenes between these molecules and for immunological recognition by specific antibodies. 
       The polypeptide chains of Igs are encoded by three non-linked cluster of autosomal 
genes, one cluster coding for H chains of all classes and subclasses, a second one for kappa 
(k) light chains and a third one for lamda (λ) light chains. These three genes clusters are called 
the H-, k-and λ gene families respectively. In humans the H gene family is on chromosome 
14, the k gene family is on chromosome 2 and the λ gene family is on chromosome 22. 
Molecular genetic studies have revealed the arrangement of gene segments within the H chain 
and L chain families. Each H chain is encoded by 4 distinct types of gene segments, 
designated VH (variable), D (diversity), JH (joining) and CH. The V region of the H chain is 
encoded by the VH, D and JH segments. The L chains are encoded by the 3 gene segments, VL, 
JL and CL segments. 
         The C gene segments of the H and L chains encode for the constant regons. Nine 
immunoglobulin H chain isotypes are found in humans: IgM, IgE, IgG (with subclasses IgG1, 
IgG2, IgG3 and IgG4) and IgA (with subclasses IgA1 and IgA2). 
        The CH gene segments determine the class and/or subclass of the H chain, whereas VH, D 
and JH regions determine the antigen-recognizing part of the Ig molecule. The H and L chains 
constant genes lie 3’ to the VH, D, JH, and VL, JL genes, respectively. During maturation of 
progenitor B cells to mature B cells an active H chain exon is formed by VH, D and JH, and 
that of L chain formed by VL and JL somatic gene rearrangements (recombined VHDJH and 
VLJL) which codes for antigen binding variable region of IgG, followed by linkage to a certain 
CH gene locus. This is transcribed to mRNA and subsequently translated to an 
immunoglobulin H chain molecule. The CH gene closest to the JH locus, the Cµ gene (IgM), 
the first isotype gene to be expressed. The other CH genes can subsequently be expressed by 
downstream switching mechanisms with simultaneous deletion of the original isotypic CH 
genes. The DNA rearrangements that underlie isotype switching and confer their functional 
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by armed effector CD4 T cells (1). 
      Comparisons of the amino acid sequences of the V regions of Igs show that most of the 
variability resides in three regions called the hypervariable regions or the complementarity 
determining regions (CDR1, CDR2 and CDR3; Fig.2). Antibodies with different specificities 
(i.e. different combining sites) have different complementarity determining regions while 
antibodies of the exact same specificity have identical complementarity determining regions 
(i.e. CDR is the antibody combining site). Complementarity determining regions are found in 
both the H and the L chains. The regions between the complementarity determining regions in 
the V region are called the framework regions. Based on similarities and differences in the 
framework regions the immunoglobulin H and L chain variable regions can be divided into 
groups and subgroups. These represent the products of different variable region genes. 
 
 
Figure 2. The antibody structure. The variable domains of both H and L chains of the Fabs 
compose the antigen- binding part of the molecule, termed Fv. Within V domains there are 
three loops designated CDRs 1, 2 and 3, which confer the highest diversity and define the 




     The most important biological activities of antibodies are related to their effector 
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bacteria, viruses, toxins). Antibodies of the IgG class exert two major effector functions: 
activation of complement and opsonisation. These effector functions, mediated via the 
fragment crystallible (Fc) region, are induced as a result of interaction of the antibody with its 
antigen via the variable Fab moiety. As consequence of antigen exposure, IgG is produced for 
long-term protective immunity. Similar to most other serum proteins, Igs of non-IgG 
subclasses have a relatively short serum half-lives (1-2 days). In contrast, the half-lives of 
most IgG antibodies are considerably longer, 6-8 days in mice (2) and 22-23 days in humans 
(3). This increases the availability of sufficient specific IgG to fight infection.  
      
 
 
  1.1.1 Immunoglobulin G Fc region 
       The Fc region is separated from the antigen binding parts of the IgG molecule by 
inding sites 




flexible hing region and forms two structural domains, the CH2 and CH3 (Fig.3). 
         Immunoglobulins are remarkable not only for the diversity of their antigen b
but also for their versatility as effector molecules. As the B cell response to an infection gets 
underway, isotype switching diversifies the functional properties of the antibody Fc region, 
which contains binding sites for other proteins and cells of the immune system (Fig.3). Fc 
regions serve two distinct functions: they deliver antibody to anatomical sites that would 
otherwise be inaccessible and they link bound antigen to molecules or cells that will affect its 
destruction. 
        The Fc o
CH2-CH interphase is the binding site for a number of proteins that bind to IgG (Fig.3), 
including protein A from Staphylococcus aureus (SpA) (4) and protein G from Streptococcus 
species (SpG) (5) the rheumatoid factor (6), the herpes simplex virus IgG binding protein gE-
gI (7), the mannose binding lectin (MBL; 8), the mannose receptor (9), the major 
histocompatibility complex (MHC) class I related neonatal Fc receptor (FcRn) (10). The 
complement protein C1q also binds the Fc portion of IgG which play a key role in the 
recognition of immune complexes (11). The binding of C1q to non-aggregated IgG is weak; 
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1.1.2 Fc receptors 
FcγRI, FcγRII, FcγRIII, C1q  









Antigen binding site 
Figure.3. A schematic representation of a human IgG isotype with its interaction 
sites. The two antigen binding sites are at the aminoterminal end of each Fab. 
Interaction site for FcγRI, FcγRII, FcγRIII and C1q are at the hinge proximal region of 
IgG-Fc, while the interaction site for FcRn, MBL, MR, SpA and SpG is at the CH2-
 
      Fc receptors are a family of cell surface molecules that bind the Fc region of the Ig-
molecule. Each members of the family recognizes Ig of one isotype or a closely related 
isotypes through a recognition domain on the heavy chain of the Fc receptor. Different cell 
types bear Fc receptors for antibodies of different isotypes. The isotype of antibody thus 
determines which types of cell will be engaged in a given responseIfunction. In humans we 
have Fc receptors for IgG, IgA, IgE and IgM.   
      The Fc receptors which include FcγRI, FcγRIIa, FcγRIIb, FcγRIII and FcRn bind to IgG, 
Fcα/µR to IgA and IgM (pIgR binds dimeric IgA and polymeric IgM), and FcεR to IgE. 
These Fc receptors play a pivotal role in linking the cellular and humoral immune responses 
by facilitating the internalization of immune complexes, antigen presentation, antibody 
dependent cellular cytotoxicity (ADCC), negative regulation of effector functions of Fc 
receptor bearing cells, regulation of the inflammatory cascade, and autoimmunity (12, 13, 14, 15) 
and Ig transport and homeostasis (discussed below). 
      The Fc receptors, except FcRn and pIgR, are composed of one or more Ig-like domains, a 
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Fc receptor γ-chain dimer. The signalling motif is called either ITAM (activating) or ITIM 
(inhibitory). FcγRI, FcγRIII, FcεRI and FcαRI are closely associated with a γ-chain dimer.  
                                                  
1.2 Human serum albumin  
 
     Human serum albumin (HSA) is 66.5 KDa globular protein, which lacks covalently 
bonded carbohydrates and lipids and is synthesized in and secreted from liver cells. The 
primary sequence of HSA shows that the protein is a single polypeptide with 585 residues 
containing 17 pairs of disulfide bridges and one free cysteine. HSA, as well as serum albumin 
from other species, has been found to consist of three homologous domains (I-III; Fig.4), 
probably derived through gene multiplication (16) each comprised of two subdomains (A and 
B) and stabilized by 17 pairs of disulfide bridges.      
     HSA is the most abundant protein in the blood plasma. Its physiological and 
pharmacological properties have been extensively studied over several decades. Such studies 
have revealed that HSA has a high affinity to a very wide range of materials. The important 
physiological role of the HSA is thought to be in the transport, distribution and metabolism of 
many endogenous and exogenous ligands (e.g. fatty acids, amino acids, steroids, metals and 
numerous pharmaceuticals), as well as to maintain the pH and osmotic balance of plasma, 
needed for proper distribution of body fluids between intravascular compartments and  
tissues.  
     It has been known for a long time that the catabolic rate of albumin is directly related to its 
serum concentration (17), but the mechanism has been unknown until recently, when it was 














Figure 4. The ribbon structure HSA molecule. HSA consists of three domains, each 
domain is marked with a different color (blue for domain D-I; yellow D-II; red, D-III). N- and 
C-termini are marked as N and C, respectively. The figure is made by pymol based on crystal 
structure. The crystal structure is from Sugio et al., Crystal structure of HSA at 2.5 A 





1.3 Major Histocompatibility Complex molecules  
        
      MHC is a set of molecules displayed on cell surfaces that are responsible for lymphocyte 
recognition and antigen presentation. The Class I and Class II MHC molecules belong to a 
group of molecules known as the Ig Supergene Family, which includes Igs, T cell receptors, 
CD4, CD8, and others. The MHC is encoded by several genes located on short arm of human 
chromosome 6.  
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There are also structurally related molecules of both classes that do not function in the 
presentation of peptide antigens to T cells: these are known as non-classical MHC molecules. 
The non-classical MHC class II molecules (DM and DO in human) regulate peptide loading 
onto classical MHC class II molecules. The non-classical MHC class I molecules are more 
numerous and diverse, and some are important in activating specialized classes of T cells. A 
notable distinction between classical and non-classical MHC molecules that bears on their 
different functions is the polymorphism of the classical MHC molecules.    
        The classical MHC class I molecules are known as human leukocyte antigens A (HLA-
A), HLA-B and HLA-C in humans and are characterized by a high level of cell surface 
expression and a very high degree of polymorphism (19). In contrast, the nonclassical class Ib 
molecules, HLA-E, HLA-F, HLA-G and other MHC class I related molecules in humans, are 
not significantly polymorphic (20). These exert their function at most levels of the immune 
response, being part of both innate and adaptive immune systems (21).                                                 
 
  
1.4. The MHC class I-related neonatal Fc receptor 
      
1.4.1 Brief overview 
 
         Reflecting the central role of IgG in the immune system, mammals have evolved 
complex mechanisms to transmit immunity from mother to young and to protect IgG from 
catabolism. Knowledge as to how serum IgG levels are maintained at constant levels in the 
circulation is of central importance in understanding the regulation of humoral immunity.        
         Brambell et al. (87), about 40 years ago, put forward a hypothesis to explain serum IgG 
homeostasis. This hypothesis proposed that salvage receptors in cells of unknown type acted 
to bind and recycle pinocytosed IgG molecules back into the serum. He also suggested that 
these receptors were involved in the transmission of maternal IgG from mother to young. The 
putative receptors were believed to be saturable, so that any IgG molecules not receptor bound 
following pinocytosis would suffer degradation. This hypothesis was put forward in the 
absence of any knowledge of the receptor or cell types involved, but at the conceptual level, 
provided a satisfactory model by which IgG homeostasis could be maintained.        
         FcRn was originally identified as the receptor responsible for IgG binding to the 
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Simister and Mostov in 1989 (23). Cloning and sequencing of this gene showed that FcRn is a 
MHC class I homolog and expanded the function of these class molecules beyond their 
known role in antigen presentation (23).  
         Further, the genes encoding both mouse and human FcRn (hFcRn) alpha chains have 
been isolated (24, 25). The rodent and human genes share homology, with mouse and rat FcRn 
being highly related and the human form more divergent. The identification of hFcRn in 
human syncytiotrophoblast (25, 26, 27) led to the suggestion that it plays a role in the 
maternofetal transfer of IgGs. The isolation and characterization of hFcRn provided an 
important link between studies of FcRn in rodents and humans. 
 
1.4.2 The structure of neonatal Fc receptor 
 
        The neonatal Fc receptor (FcRn) is a type I glycoprotein heterodimer that comprises a 
glycosylated heavy chain (45 kDa for humans and 51 kDa for rodents) in non-covalent 
association with a soluble light chain consisting of 12 kDa β2 microglobulin (β2m) (Fig.5).  
         Crystallographic structure of rat FcRn shows that like the heavy chain of class I 
molecules, the heavy chain of FcRn consists of three domains, α1, α2 and α3, followed by a 
transmembrane region and small cytoplasmic domain (28). However, FcRn can not bind 
peptides owing to rearrangements of its α-helices, and the counterpart of the MHC peptide 
binding groove in FcRn is filled with side chains. The rearrangement of the FcRn α2 helix 
compared to class I molecules is due to a break in the helix introduced by the presence of 
proline at position 162 resulting in closing of the groove. In class I molecules, the two 
spanning α-helices are separated by a groove (29). In all crystal structures of class I molecules 
solved sofar; the peptide-binding groove is occupied by either a mixture of endogenous 
peptides or by a single defined peptide. Owing to an overall repositioning of the α1 helix and 
bending of the C-terminal portion of the α2 helix, the FcRn helices are considerably closer 
together. Near the middle of the FcRn platform, the α2 helix moves over to fill up the space 
between the helices. Surface representations of the tops of the FcRn and the class I α1 and α2 
domains show that there is no continuous groove in FcRn. This correlates with biochemical 
results showing that soluble FcRn does not contain endogenous peptides (30). The two FcRn 
immunoglobulin-like domains α3 and β2m, superimpose closely upon the corresponding 
domains of class I molecules. Many of the heavy chain/ β2m contacts are conserved between 
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additional contacts to β2m, in that the loop between β-strands 1 and 2 of α1 domain dips 
downwards to contact β2m. 
         In contrast to extracellular domains, the transmembrane region and cytoplasmic tails of 
FcRn and MHC class I are not closely related (23). There is divergence in the cytoplasmic 
regions consistent with the different functional activities of the two types of proteins. Studies 
of rat FcRn cytoplasmic domain show presence of endocytosis signals (31). Tryptophan at 
position 311 and dileucine motif are necessary components of endocytosis signals. Leucine at 
position 322 and 323, together with aspartic acid at position 317 and/or 318 are parts of a 
typical dileucine-based endocytosis signal (31). In polarized cell models, FcRn in the plasma 
membrane is predominantly at basolateral surface. This distribution depends on signals that 
overlap endocytosis signal. The tryptophan-based basolateral targeting, which requires the 
aspartate pair of the dileucine based-signal, and endocytosis signals are distinct but 
overlapping (32).  
        The amino acids sequence analysis of mouse and rat heavy chains share 91% identity (24) 
while the hFcRn heavy chain shares 65% amino acids identity with its rat homologue (25). In 
spite of its similarity to MHC class I, the FcRn heavy chain is encoded outside the MHC, on 
chromosome 7 in mice and chromosome 19 in humans. FcRn heavy chains are non.covalently 
associated with β2m, the class I light chain.  
        The β2m which is required for both surface expression and function of FcRn (33) is 
encoded on chromosome 15 in humans. Indications that an association of the FcRn heavy 
chain with β2m is important for the assembly of a functional receptor come from β2m-
knockout mice (34), which showed defects in several functions associated with FcRn. 
Newborn β2m-deficient pups show lower IgG serum level at birth and accumulate less IgG 
before weaning than normal littermates (34). Further, adult mice lacking β2m have a higher 
IgG turnover, resulting in lower serum IgG levels (35, 36, 37). Expression of the hFcRn α-chain 
alone or in combination with β2m in human melanoma FO-1 cells (FO-1) showed that β2m is 
important for cell surface expression of FcRn and that, in the absence of β2m, the receptor is 
retained in the endoplasmic reticulum (38). In the absence of β2m, IgG binding is decreased 
compared with that of native FcRn. Thus, assembly of the FcRn heavy chain with β2m is 
important for both transport of FcRn from the endoplasmic reticulum to the cell surface and 













Figure 5. Ribbon structural diagrams of hFcRn, rFcRn, and the class I MHC molecule (HLA-




1.4.3 FcRn interacts with its ligands in a pH-dependent manner 
 
         Studies have indicated that the distinguishing feature of FcRn interaction with its ligands 
is its strict pH dependence, with binding at acidic pH (6-6.5), and undetectable interaction at 
slightly basic pH (7.4) (39). No conformational change is observed between the structures of 
FcRn at pH 6.5 and pH 8 that could account for the differences in affinity for IgG (40). Rather, 
the pH-dependent FcRn-ligand binding are mediated by electrostatic interactions attributed to 
conserved amino acid residues located at the CH2-CH3 domain of IgG-Fc (Table 1). This 
involves mainly the imidazole groups on H310 and H435 (Fig. 6A) of IgG which are 
positively charged and facilitate interaction with negatively charged residues in the FcRn α2-
domain, whereas at physiological pH 7.4, the side chains are neutral. The main FcRn α2-
domain residues involved are E117, E118, D137 and E135 (Fig. 6B).   
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Table 1.  Variations of IgG sequences in the region involved in the binding of FcRn 
 
 
   The table is taken from Gethie and Ward (2000) 
    
        Reports show that FcRn also binds HSA in a pH dependent manner (18). Studies in FcRn-
deficient mice have shown that the half-life and the steady-state concentration of albumin 
were decreased relative to wild-type mice. The hypothesis that FcRn binds both IgG and HSA 
is also evidenced by a β2m gene mutation that underlies the hypercatabolism and reduced 
serum levels of HSA and IgG in the two siblings with familial hypercatabolic 
hypoproteinemia (41). This experiment of nature confirms that FcRn binds both HSA and IgG. 
        FcRn binds both HSA and IgG simultaneously in a pH dependent manner (42). The pH 
dependence of the FcRn-albumin interaction suggests that, like IgG, albumin binding to the 
receptor might also be mediated through titratable histidine residues. Andersen et al. (43) 
compared the sequence of the FcRn α2-domain from eleven different species, and identified 
histidine residues that were conserved in all (H166) or seven (H161) of these species (Fig.7), 
and showed that the conserved H166 (Fig. 8) is a key player in the FcRn-albumin interaction. 
The corresponding interacting residue on HSA is probably negatively charged and surface 
exposed on domain III. The experiments measuring binding of FcRn to the three recombinant 
albumin domains establish that albumin D-III alone is both necessary and sufficient for 
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Figure 6. (A) pH sensitive histidine residues in the Fc CH2-CH3 interphase of IgG important 
in the FcRn interaction. (B) Shows FcRn α2-domain involved in binding to IgG. Figure is 
taken from Annu.Rev.Immunol.2000.18.739-766. 
 
 
Figure 7. Alignment of predicted α2-domain amino acid sequences from eleven FcRn 
heavy chain. Sequences (rat, mouse, human, macaque, orang-utan, pig, camel, sheep, cattle, 
dog and possum). Amino acid residues that are identical in all sequences are indicated by (*), 
conserved substitutions are indicated by (:), semi-conservative substitutions are indicated by 
(.). The potential N-linked glycosylation site is highlightened by filled circle (●). Amino acid 
residues involved in IgG binding are indicated by downward arrow and partially or fully 
conserved histidine residues (hFcRn heavy chain; H161 and H166A) are indicated by open 












Figure 8. Localization of relevant hFcRn α2-domain residues. A ribbon diagram of the 
crystal structure of shFcRn, the heavy chain is displayed in blue, β2m in green. The IgG 
interacting residues (E115, E116, D130, W131 and L135) are marked as yellow balls and the 
two α2-domain located histidine residues, H161 and H166, are marked in purple. The figure 
are taken from Andersen et al., (2006). 
 
 
1.4.4 The stoichiometry of the FcRn-ligand interaction 
 
        To understand FcRn functions, it is important to explore the structural bases of pH-
dependent IgG-FcRn interaction. In this context, studies have been carried out and different 
models forwarded to show the stoichiometry of the interaction between IgG and FcRn.  
        The stoichiometry of the interaction between soluble FcRn and Fc has been reported as 
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FcRn to one CH2-CH3 domain interface site precludes an FcRn:Fc interaction at the second 
site (45). Further crystallographic studies show that rat FcRn can interact with the Fc portion 
of IgG in a repeating array in which FcRn dimers are bridged by Fc fragme nts to create an 
"oligomeric ribbon" with a 2n:n stoichiometry. Analysis of complexes formed in solution 
between soluble rat or mouse FcRn and Fc showed that both forms of FcRn produce 2:1 
receptor-ligand complexes, but that alterations of the carbohydrate moieties on mouse FcRn 
can result in an apparent stoichiometry of 1:1 (46).  
         The crystal structure of hFcRn has been determined and compared to the previously 
described structure of rat FcRn and to the structures of MHC and MHC-related proteins. 
Human FcRn is structurally similar to the rat receptor but does not form receptor dimers in the 
crystals as observed in crystals of rat FcRn (47). The interaction between hFcRn and IgG was 
characterized by determining the binding stoichiometry using equilibrium gel filtration and by 
deriving binding affinities for the different human IgG subclasses using a surface plasmon 
resonance assay (47). Like rat and mouse FcRn, hFcRn interacts with IgG with a 2:1 
receptor:ligand stoichiometry. The binding of hFcRn to the four human IgG subclasses shows 
subclass and allotype variations but no clear subclass affinity differences that correlate with 
serum half-lives (47). Further evidences are required for elucidation of the disparities among 
these different models explaining the stoichiometry of interaction between FcRn and IgG.  
 
 
1.4.5 Preferential binding of hFcRn with IgG    
 
         Although mice are widely used in the pre-clinical testing of antibodies, human and 
mouse FcRn have significant differences in binding specificity. It is established that FcRn is 
the receptor that salvages from degradation and regulates the serum half-life of IgG in mice. 
Reports indicate that the human homologue of mouse FcRn serves similar functions in 
humans. Mouse IgG is promiscuous in binding specificity and binds to all IgG of species 
analysed, including human, mouse, rat, guinea pig, bovine, sheep, and rat IgG. In contrast, 
hFcRn is surprisingly stringent, and only interact well with human, rabbit and guinea pig IgGs 
(48).  
         Human FcRn does not bind detectably to mouse IgG1, IgG2a, and shows a very weak 
interaction with mouse IgG2b. The high selectivity of the hFcRn-IgG interaction therefore 
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human circulation (49, 50). 
     
1.4.6 Multiple functions of FcRn 
 
1.4.6.1 Transfer of immunity (passive immunization) 
 
         Passive acquisition of antibody is important to the newborn prior to the development of 
a fully functional immune system. Transfer of maternal IgG to the fetus or infant humoral 
immunity to antigens encountered by the mother. Transmission of IgG is mediated by the 
neonatal Fc receptor.  
         In newborn rodents, FcRn on the apical side of intestinal enterocytes bind to maternal 
IgG in ingested milk, escort the IgG across the gut epithelium, then release it into the blood 
stream from the basolateral surface in the process of transcytosis (51, Fig.9a). The pH 
difference between the apical (pH 6.0-6.5) and basolateral (pH 7.0-7.5) sides of intestinal 
epithelial cells ensures efficient unidirectional transport of IgG. 
         Although the acidic pH at the apical surface of intestinal epithelial cells permits cell 
surface FcRn to bind IgG, FcRn can also function in IgG transport when there is no net pH 
gradient. FcRn transports IgG across the syncytiotrophoblastic cells of the human placenta 
(reviwed in 51) in this way. For this function, it is believed that IgG in the blood (pH 7.4) 
enters cells in a receptor-independent manner via fluid phase endocytosis, after which it is 
delivered to acidic endosomes where it binds to FcRn (Fig.9a). Upon delivery of FcRn-IgG 
complexes to the cell surface, the slightly basic pH of the blood causes IgG release into the 
circulation.  
        An ex vivo placental model has been used to analyze the maternofetal transfer of a 
recombinant, humanized (IgG1) antibody in which His435 has been mutated to alanine 
(H435A). In vitro binding studies using surface plasmon resonance indicate that the mutation 
ablates binding of the antibody to recombinant mouse and human FcRn (52). Relative to the 
wild-type antibody, the H435A mutant is deficient in transfer across the placenta. 
Significantly, the mutation does not affect binding to Fc gamma RIII, an FcR that has been 
suggested in earlier studies to mediate the transfer of maternal IgG (53). The analyses 
demonstrate that binding of an IgG to FcRn is a prerequisite for transport across the perfused 
placenta (52). FcRn therefore plays a central role in the maternofetal delivery of IgG and this 








        The placental barrier between maternal and fetal circulatory systems, across which IgG 
must pass, consists of two cell layers and an intervening stroma (54). The first of these cell 
layers is the epithelial syncytiotrophoblast, which completely covers chorionic villi and 
constitutes the point of direct fetal contact with circulating maternal blood. Once across the 
syncytiotrophoblast, IgG appears to transit the villus interstitium via bulk fluid flow (55, 56). 
How IgG crosses the fetal villus capillary endothelial cell layer is not known. 
 
1.4.6.2 Maintenance of IgG and HSA homeostasis 
 
         In addition to mediating the transfer of maternal IgG, FcRn is also important in 
regulating the amount of IgG in serum. Because a high concentration of IgG bathes most 
cells, it is readily internalized by non-specific mechanisms of fluid-phase endocytosis. Unlike 
most other protein solutes internalized by fluid phase endocytosis, however, IgG is rescued 
from degradation in the lysosome by FcRn (57). FcRn binds to IgG and recycles it back to the 
plasma membrane and into circulation. Once FcRn binding is saturated, the non-receptor 
bound IgG is delivered along with other fluid phase cargo to the lysosomes, where it is then 
degraded (Fig.9b). Therefore, IgG level in serum are governed by the saturable nature of the 
intracellular FcRn-IgG interaction (51). As early as in 1966, a mechanism identical to that 
proposed by Brambell for protecting IgG from degradation was applied to albumin as well. 
The inverse relationship between serum albumin concentration and its half life suggested that 
albumin would be protected from a catabolic fate by a receptor-mediated mechanism much 
like that proposed for IgG. Recently, this was confirmed when it was shown that hFcRn binds 
not only hIgG but HSA as well (18). The FcRn-mediated recycling has been shown to save as 
much albumin from degradation as the liver produces (58). It follows that FcRn diverts not 
only IgG but albumin as well from a degradative fate by similar pH-dependent mechanisms, 
prolonging the lifespan of both molecules. It has been suggested that endothelial cells of small 
arterioles and capillaries involve in these functions (59).  It is possible that the organ separated 
from blood by fenestrated or discontinuous endothelium may participate in similar function 







                                                                    27 
  
 
1.4.6.3 Bidirectional transmission of IgG across mucosal barriers 
 
        Humoral immunity as mediated by IgG plays an important role in mucosal tissues as a 
defense against pathogens. Within the gastrointestinal, respiratory and genitourinary tracts 
immunoglobulins access to mucosal secretions must occur in the context of a barrier imposed 
by epithelial cells that separates the host from the external environment.  
        The FcRn is involved in the bidirectional transmission of IgG/immune complex across 
mucosal barriers (60, 61) (Fig.9C). The FcRn can then transport the IgG/antigen complex back 
across the intestinal barrier into the lamina propria for processing by dendritic cells and 
presentation to CD4(+) T cells for subsequent immune activation (62). This mechanism has 
been associated with defense against an epithelium-associated pathogen Citrobacter 
rodentium (62). In addition, neonatal mice have been shown to be protected against the 
luminal parasite Heligmosomoides polygyrus by IgG delivered directly in milk or via FcRn 
from the neonatal serum into the intestinal lumen to exert its protective effect (63). Thus, FcRn 
through its ability to bind and release IgG, integrates luminal antigen encounters with 
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 Figure 9. Mechanisms of FcRn functions: (a) IgG transport. At acidic pH (6.0-6.5) IgG 
will bind to FcRn on the surface of the cell (step 1). Where the pH outside the cell is neutral, 
IgG is internalised by fluid face endocytosis (step 2) and then FcRn binding occurs in the acid 
intracellular compartment. FcRn-IgG complex are transported to basolateral surface (step 3), 
where the pH is basic. (b) Regulation of IgG homeostasis. In endothelial cells IgG is taken 
up by fluid phase endocytosis and delivered to endosome (step 1), where it interacts with 
FcRn. Ligand bound to receptor is either recycled to apical plasma membrane where it 
returned to blood (step 2) or transported to and released at basolateral pole  of the cell (step 3). 
When IgG concentration is high, unbound IgG is delivered to lysosomal degradative 
pathwayalong (step 4). (c) FcRn-IgG in immune activation and tolerance. IgG is taken in at 
basolateral phase of the cell (step 1) and transported by FcRn to the apical pole of the cell, 
where it is released at the surfaceto the (step 2). FcRn-IgG-antigen complexes internalized by 
fluid phase endocytosis or through their interaction with FcRn (step 3) transported to 
basolateral pole of the cell (step 4), delivering immune complexes to the lamina propria for 
subsequent induction of immune activation or tolerance (step 5). The illustration is taken from 
Rojas and Apodaca (2002 ) 
 
 
                          
1.4.6.4 Roles of FcRn in immune cells. 
 
         Studies have shown that FcRn is functionally expressed by monocytes, macrophages, 
dendritic cells and monocytic cell lines such as THP-1 cells (64) but  established cell lines 
derived from B-lymphocyte, T-lymphocyte, and NK cell lineages failed to express FcRn 
heavy chain (64). FcRn is also expressed in polymorphonuclear neutrophils (65). 
          Recent study shows that FcRn is highly expressed in freshly isolated human and mouse 
neutrophils (PMNs) and IgG-mediated phagocytosis by these cells was facilitated by FcRn 
(65). It was found that FcRn enhances phagocytosis in a pH-dependent manner. IgG-opsonized 
bacteria were inefficiently phagocytosed by neutrophils from β2m knock-out or FcRn α-chain 
knock-out mice, which both lack expression of FcRn. Similarly, low phagocytic activity was 
also observed with mutated IgG (H435A), which is incapable of binding to FcRn, while 
retaining normal binding to classical leukocyte Fcγ receptor. They observed FcRn 
translocation to nascent phagosomes, where FcRn facilitates IgG-mediated bacterial 
phagocytosis through signalling motifs found within the cytoplasmic tail. These results point 
to a novel role for FcRn in phagocyte biology (65).   
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1.5 Relevance of FcRn in therapeutics 
 
        The FcRn plays an essential role in extending the half-life (t(1/2)) of IgG antibodies and 
IgG-Fc-based therapeutics in the circulation. The role of FcRn in the regulation IgG 
homeostasis suggests that the modulation of IgG binding affinities for FcRn might be an 
effective approach for the treatment of IgG-mediated disease.   
         Several studies have demonstrated a correlation between the binding affinity of IgGs to 
FcRn and their serum half-lives in mice, including engineered antibody fragments with longer 
serum half-lives (66). Studies also extended this correlation to human IgG2 antibody variants 
in primates (67). Further, several human IgG1 mutants with increased binding affinity to 
hFcRn at pH 6.0 were generated that retained pH-dependent release. A pharmacokinetics 
study in rhesus monkeys of the IgG1 variants indicated that its serum half-life was 
approximately 2.5-fold longer than the wild-type antibody (68). Antigen binding was 
unaffected by the Fc mutations, while several effector functions appeared to be minimally 
altered. These properties suggest that engineered antibodies with longer serum half-lives may 
prove to be effective therapeutics in humans (68) 
        Engineering the Fc region of a hIgG to generate a mutated antibody that modulates the 
concentrations of endogenous IgGs in vivo has been shown. An IgG whose Fc region was 
engineered to bind with higher affinity and reduced pH dependence to FcRn potently inhibits 
FcRn-IgG interactions and induces a rapid decrease of IgG levels in mice (69). Such FcRn 
blockers (or 'Abdegs,' for antibodies that enhance IgG degradation) may have uses in reducing 
IgG levels in antibody-mediated diseases and in inducing the rapid clearance of IgG-toxin or 
IgG-drug complexes. The Abdeg design is to alter the level of endogenous, unmanipulated 
IgGs by enhancing their clearance rates.  
         FcRn blockade by intravenous Ig (IVIG) significantly increases the catabolism of serum 
IgG in mice (70). Studies on the therapeutic effects of an anti-rat FcRn mAb, 1G3, in two rat 
models of myasthenia gravis resulted in dose-dependent amelioration of the disease symptoms 
after passive experimental autoimmune myasthenia gravis was induced by administration of 
an anti-acetylcholine receptor (AChR) mAb (71). The effect of 1G3 was also studied in an 
active model of experimental autoimmune myasthenia gravis in which rats were immunized 
with AChR. Treatment with 1G3 significantly reduced the severity of the disease symptoms 
as well as the levels of total IgG and anti-AChR IgG relative to untreated animals. These 








         In imaging, it is desirable to have a short half-life and, although this can be achieved by 
using Fab fragments, it is now also possible to engineer complete antibodies with single 
amino acid substitution (e.g. Ile253 to Ala) (72, 73), which have reduced serum persistence.  
          Since it was recently discovered that HSA binds to FcRn and extends its lifespan, there 
may be focus on the possibility of constructing albumin coupled drugs, as these will have 
FcRn binding properties and a prolonged in vivo half-life. 
          Retargeting T lymphocytes to tumor cells for destruction by recombinant bispecific 
antibodies (e.g. single chain dibody) have been reported. However, therapeutic efficacy is 
hampered by a short serum half-life of these small molecules having molecule masses of 50-
60 kDa. Thus, improvement of the pharmacokinetic properties of small bispecific antibody 
formats is required to enhance efficacy in vivo. Taking advantage of long half-life conferred 
by FcRn, recombinant bispecific antibody-albumin fusion proteins were generated and fusion 
to HSA strongly increases circulation time for biological activity and pharmacokinetic 
properties (74). Rapid targeting, excellent tumor deposition and retention, coupled with high 
tumor to blood ratios may make albumin.Fab fusion an exceptional molecule for imaging and 
cancer therapy (75).  
          As FcRn targeting drug, delivery of erythropoietin (Epo) conjugated to the Fc domain 
of IgG1 in mouse and non-human primates has been reported (76, 77). FcRn-dependent 
absorption was most efficient when the Epo-Fc fusion protein was deposited predominantly in 
the upper and central airways of the lung, where epithelial expression of FcRn was most 
prominently detected. The bioavailability of the EpoFc monomer when delivered through the 
lung was approximately equal to that reported for unconjugated Epo delivered s.c. in humans 
(Bitonti et al., 2004). This points to a functional FcRn-dependent transport pathway in the 

















The MHC class I related neonatal Fc receptor, FcRn was first described functionally in 
rodents as the receptor that transfers IgG in the maternal milk from the intestine of neonate 
rodents to the blood stream (39, 78). The human form of FcRn was identified in the placental 
syncytiotrophoblast, showing that this receptor plays a role in passive immunization of the 
fetus by maternofetal transport of IgG (27, 81, 82, 25).  
     Subsequent studies have shown FcRn mRNA in many tissues of adult rats, mice and 
humans, and FcRn is present in several adult tissues and in cell lines. In addition to mediating 
the transfer of maternal IgG, FcRn is also important in regulating the amount of hIgG in 
serum by prolonging its half-life. Reports show that FcRn also binds HSA in a pH dependent 
manner (18).  
   A hallmark of FcRn interaction with its ligands is its strict pH dependence. The binding 
occurs at the cell surface or in the intracellular vesicles where the pH is 6.0-6.5, while IgG is 
released at pH 7.0-7.5 (39, 88).  
 
2. Methods: Cell culture, RT-PCR, ELISA, Western immunoblotting and flow cytometry 
 
3. The aims of the study are to investigate: 
 
  1. Expression of FcRn in human immune cells and hepatocytes. 
  2. Ligand binding properties of soluble and membrane-bound FcRn. 
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         Expression and diverse functions of MHC class I related neonatal Fc receptor in 
different tissues is continually reported. To contribute to the understanding of how the 
receptor functions according to cell type, we investigated the expression and ligands binding 
properties of FcRn in human immune cells and hepatocytes. Here, we report that 
heterodimeric FcRn is expressed in these cells as evidenced by RT-PCR, Western 
immunoblottting and flow cytometry. The receptor expression is shown to be predominantly 
intracellular as compared to that on the surface. Our report on human hepatocytes and 
monocytic K-562 cells is for the first time. In addition, the human hepatic cell lines were 
shown to express FcγRII but no evidence of FcγRI and FcγRIII. Our pH dependent cell 
binding assays have demonstrated increased binding of hIgG and HSA to membrane-bound 
hFcRn at acidic pH in these cells and the pH dependent binding of IgG is Fc mediated. The 
increased binding of IgG and HSA at acidic pH is completely mediated by FcRn as shown by 
anti-FcRn inhibition and not affected by isotype goat IgG. It was found that IgG and HSA 
bind to the membrane-FcRn independently of each other and this is the first report of pH 
dependent HSA binding to a membrane-bound hFcRn. Moreover, we have shown that anti-
inflammatory substances such as both naturally occurring and synthetic glucocorticoids, and 
L-thyroxine clearly downregulate the FcRn expression in human monocytic U-937 and 
hepatic cell lines. 
























     
     IgG and HSA are the most abundant of the serum proteins and their long half-life is due to 
FcRn binding properties.       
     The FcRn was first described functionally in rodents as the receptor that transfers IgG in 
the maternal milk from the intestine of neonate rodents to the blood stream (1, 2). 
Subsequently, the isolation and characterization of rat FcRn from the yolk sac endoderm led 
to the proposal by Roberts et al (3) that this Fc receptor was involved in the maternofetal 
transfer of IgGs. The human form of FcRn was identified in the placental syncytiotrophoblast, 
suggesting that this receptor plays a role in passive immunization of the fetus by maternofetal 
transport of IgG (4, 5, 6, 7). Subsequent studies have shown FcRn mRNA in many tissues of 
adult rats, mice and humans, and FcRn is present in several adult tissues and in cell lines. 
      FcRn is a MHC class I related molecule that comprises a glycosylated heavy chain (45 
kDa for humans and 51 kDa for rodents) in non-covalent association with β2m (12 kDa). 
Assembly of the FcRn heavy chain with β2m is important for both transport of FcRn from the 
endoplasmic reticulum to the cell surface and functions (8, 9). 
     In addition to mediating the transfer of maternal IgG, FcRn is also important in regulating 
the amount of hIgG in serum by prolonging its half-life. The rate of IgG turnover increases as 
the amount of IgG in the serum rises (10). Turnover occurs in endothelial cells and involves a 
saturable process that is FcRn mediated (11).  This has been demonstrated in β2m deficient 
mice that have abnormally low IgG half life in comparison to control animals (12).  
The FcRn is also involved in the bidirectional transmission of IgG/immune complex across 
mucosal barriers (13, 14). The FcRn can then transport the IgG/antigen complex back across the 
intestinal barrier into the lamina propria for processing by dendritic cells and presentation to 
CD4(+) T cells for subsequent immune activation (15). This mechanism has been associated 
with defense against an epithelium-associated pathogen Citrobacter rodentium (15). In 
addition, neonatal mice have been shown to be protected against the luminal parasite 
Heligmosomoides polygyrus by IgG delivered directly in milk or via FcRn from the neonatal 
serum into the intestinal lumen to exert its protective effect (16). Thus, FcRn integrates 
luminal antigen encounters with systemic immune compartments and, as such, provides 
essential host defense at the mucosal surfaces.   
     A distinguishing feature of FcRn interaction with IgG is its pH dependence. The binding 
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released at pH 7.0-7.5 (1, 17). IgG molecules that do not bind to FcRn are delivered to the 
default lysosomal pathway and degraded (18). The interaction site for hFcRn on IgG has been 
mapped and shown to encompass conserved residues at the CH2-CH3 domain interphase, and 
these residues include Ile253, His310 and His435 (19, 20, 21, 22, 23). The IgG histidine residues 
regulate the pH dependent interaction, resulting in stronger binding at acidic pH relative to 
neutral pH. In addition, it has been shown that the interaction between hFcRn and IgG is 
highly stringent as hFcRn only shows binding to a limited number of species. In contrast, 
rodent FcRn does not show this stringency (24). It has been shown that residue Leu137 of 
hFcRn is responsible for this specificity (25). 
      Reports show that FcRn also binds HSA in a pH dependent manner (26). Studies in FcRn-
deficient mice have shown that the half-life and the steady-state concentration of albumin 
were decreased relative to wild-type mice. The FcRn-mediated recycling has been shown to 
save as much albumin from degradation as the liver produces (27). It follows that FcRn diverts 
not only IgG, but albumin as well from a degradative fate by similar pH-dependent 
mechanisms, prolonging the lifespan of both molecules. 
    FcRn binds both HSA and IgG simultaneously (28). A recent report has shown that the 
conserved H166 residue in the α2-domain of hFcRn heavy chain has a central role in 
facilitating the pH-dependent binding to HSA (29). The corresponding interacting residue on 
HSA is probably negatively charged and surface exposed on domain III (28). Significantly, 
H166 is conserved in eleven species investigated, and this strongly suggests that FcRn utilizes 
a common mechanism for maintaining albumin concentration at high levels in all these 
species (29). The IgG interacting residues on FcRn α2-domain are E115, E116, D130, W131 
and L135.   
       Recently, studies have shown that FcRn is also functionally expressed by monocytes, 
macrophages, DCs, PMNs and monocytic cell lines such as THP-1 cells (30) but not in B-
lymphocyte, T-lymphocyte, and NK cell lineages (30, 31). The functional role in immune cells 
is far from fully understood, but recent data show that FcRn enhances phagocytosis in a pH-
dependent manner. IgG-opsonized bacteria were inefficiently phagocytosed by neutrophils 
from β2m and or FcRn heavy chain deficient mice, similarly, low phagocytic activity was 
observed with mutated IgG (H435A), which is incapable of binding to FcRn, while retaining 
normal binding to the classical leukocyte Fcγ receptor. In addition, FcRn translocation to 
phagosomes was shown to be facilitated through signalling motifs found within the FcRn 




                                                                    44 
  
 
    Even though the binding of IgG to FcRn in immune cells has been described, there is no 
report on HSA binding and its functional consequences. 
        The presence of polymerized albumin receptor on Hep-G2 cell has been reported, and 
purified hepatitis B virus attach to the cells via this receptor. Synthetic peptides analogous to 
part of its surface protein were used to study polymerized albumin-dependent attachment of 
the virus to Hep-G2 cells. Antibodies raised against the peptide were used to inhibit the 
hepatitis B virus attachment to HepG2 cells. Polymerized albumin has specific saturable 
receptor on HepG2 cells with two classes of binding sites (40). 
         Further studies suggest that polymeric human serum albumin may facilitate the 
attachment of the virus during the infectious process. Hepatocytes showed binding activity for 
both polymeric and monomeric albumin from different species. The receptor-ligand 
interaction was temperature and pH dependent (42). These findings suggest that human 
hepatocytes display species-non-specific albumin binding sites, which are glycoproteins (42). 
    FcRn has been shown to be functionally expressed on the surface of adult rat hepatocytes 
and hypothesized to mediate transport of IgG from serum to bile (13). However, other report 
shows that serum to bile transport of IgG was unaffected in mice functionally deleted for 
FcRn (32). Accordingly, the hypothesis is rejected that FcRn functions as sorting receptor in 
liver. In contrast, FcRn in hepatocytes has been implicated in protecting IgG from the 
catabolism that accompanies endocytic activity these cells (32). Eventhough the expression of 
FcRn is reported in rat hepatocytes no data from human studies exist. In addition, there are 
disparities about FcRn functions in hepatocytes as related to IgG and HSA homeostasis. 
Taken together, the expression of FcRn in immune cells and hepatocytes, and its functional 
importance in relation to IgG and HSA homeostasis, and IgG-mediated phagocytosis demand 
further investigations. 
     In the present study, we investigated the expression and functional binding of IgG and 
HSA to human immune cells (monocytic U-937, THP-1, K-562) and freshly isolated 
peripheral blood mononuclear cells (PBMC). We found that both ligands showed increased 
binding at acidic pH to membrane-bound FcRn, and the receptor-ligand interactions were 
blocked by excess amount of IgG, HSA, protein G or polyclonal anti-FcRn antibodies. This is 
the first report demonstrating HSA binding in a pH dependent fashion to a membrane-bound 
FcRn. 
     In addition, we report that FcRn is expressed in human hepatic cell lines (Hep3B and 
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to both IgG and HSA at acidic pH. Assessments of other Fcγ receptors show that FcγRII 
(CD32) is expressed but not FcγRI (CD64) and FcγRIII (CD16). We also demonstrate that 
treatment of anti-inflammatory substances clearly downregulate FcRn expression in both 
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            ABBREVIATIONS 
                                                                            
Ab                                           Antibody 
AChR                                     Anti-acetylcholine receptor      
BCA                                        Bicinchoninic acid 
C-terminus                             Carboxy terminus 
DC                                           Dendritic cells 
Epo                                          Erythropoietin 
Fab                                          Fragment antigen binding 
Fc                                             Fragment crystallible 
FcRn                                       Neonatal Fc receptor 
FITC                                       Fluorescein isothiocyanate 
hFcRn                                     Human FcRn 
hIgG                                        Human IgG 
HLA                                        Human leukocyte antigen 
HSA                                        Human serum albumin 
HSV                                        Herpes simplex virus 
Hep                                         Hepatic 
Ig                                             Immunoglobulin 
ITP                                          Immune thrombocytopenia 
IVIG                                        Intravenous Ig therapy 
MDCK                                    Madin-Darby canine kidney 
mIgG                                       Mouse IgG 
N-terminal                              Amino terminal 
rFcRn                                      Rat FcRn 
shFcRn                                    Soluble human FcRn 
SPR                                         Surface plasmon resonance 
WT                                          Wild type  
BSA                                         Bovine serum albumin 
β2m                                          β2-microglobulin 
CIP                                          Calf intestinal phosphatase 
E.coli                                       Escherichia coli 
FCS                                         Foetal calf serum 
HRP                                        Horseradish peroxidase 
hβ2m                                       Human β2-microglobulin 
ON                                          Over night 
OriP                                        Origin of replication 
PCR                                        Polymerase chain reaction 
RT-PCR                                 Reverse transcriptase PCR  
PS                                            Penicillin 
PBMCs                                   Peripheral blood mononuclear cells 
RPM                                       Round per minute 
RT                                           Room temperature 
SDS-PAGE                            Sodium dodecyl polyacrylamide 
Skm                                        Skimmed milk 
ELISA                                    Enzyme-linked immunosorbent assay 
TM hFcRn                             Transmembrane human FcRn 
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3.  Materials and methods 
 




          The eukaryotic vector pcDNA3 (Figure 1A) was originally from Invitrogen (Grand 
Island, NY). It was modified with a gene encoding glutathione S-transferase (GST) 
inserted into the polylinker on restriction sites XhoI and ApaI giving rise to pcDNA3-
GST vector. As such it was a gift from F. E. Johansen (The National Hospital, Oslo, 
Norway). The vector was further modified with cDNA encoding extracellular part of 
human FcRn (hFcRn) heavy chain inserted into the polylinker at EcoRΙ and XhoΙ  
restriction sites and cDNA encoding human β2-microglobulin (hβ2m) in the restriction 
site NruΙ resulting in the pcDNA3-FcRn-GST.Pcmv-beta2m-polyA vector (Figure 1B; 
Berntzen et al, 2005). The vectors pEGFP-N1, pECFP-N1, pERFP-N1 and pEYFP-N1 
(BD Biosciences Clontech, Qume Drive, San Jose, CA, USA) were gifts from Oddmund 
Bakke (IMBV, University of Oslo, Norway). A schematic representation of pEGFP-N1 is 
shown in figure 2. 
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Figure 1. Plasmid maps 
A. The original vector map for pcDNA3 as it appears in the vector catalogue available at: 
http://www.invitrogen.com. B. The map shows pcDNA3-FcRn-GST.Pcmv-beta2m-polyA 
with the sequence encoding the extracellular part of hFcRn heavy chain in the polylinker 
between the restriction sites EcoRI and XhoI, and hβ2m in the NruΙ site. CMV: promoter 
for cytomegalovirus, BGH pA: polyadenylation signal from the bovine growth hormone 
gene, SV40ori: origin of replication from SV40 virus, SV40: the promoter from SV40 
virus, ColE1: origin, Ampicillin: resistance gene for replication in bacteria, Neomycin: 
resistance gene for selection of stable expression in mammalian cells, T7: the T7 
promoter, Sp6: the Sp6 promoter. The complete vector sequence for pcDNA3 is available 
at: http://www.invitrogen.com. The illustration of the pcDNA3-GST vector was 
performed using the programme pDRAW32 available at: http://www.acaclone.com. 





Figure 2. Plasmid map 
The original vector map for pEGFP-N1 as it appears in the vector catalogue available at: 
www.bdbiosciences.com. CMV IE: Human cytomegalovirus immediate early promoter 
MCS: multiple cloning sites, EGFP: Enhanced green fluorescent protein gene, SV40 
polyA: Early mRNA polyadenylation signal, f1 ori: single-strand DNA origin, P: SV40 
early promoter, SV40 ori: SV40 origin of replication, Kan /Neo: Kanamycin/neomycin 
resistance gene, HSV TK: Herpes simplex virus tyymidine kinase polyadenylation signal, 





                                                                               




3.1.2 The Wizard™ Plus Minipreps DNA Purification System 
 
          The Wizard™ Plus Minipreps DNA Purification System from Promega (Madison 
WI, USA) was routinely used for small-scale purification of plasmid DNA. Plasmid DNA 
was purified using reagents and anion exchange resin columns supplied with the kit. The 
purification was done as described in the protocol. The minipreps were eluted in distilled 
H2O (dH2O), and their DNA concentration and purity were determined by 
spectrophotometric measurement (A 280/260nm) on a GeneQuant spectrophotometer 
(Amersham Pharmacia Biotech, UK). The integrity of plasmid constructs were confirmed 
by restriction analysis, agarose gel electrophoresis and verified by sequencing by GATC 
(Gmbh, Konstanz, Germany). 
 
3.1.3 The Wizard™ Plus Midipreps DNA Purification System 
 
          Prior to transfection of the plasmid constructs, the plasmids were isolated using the 
The Wizard™Plus Midipreps DNA Purification System (Promega). Plasmid DNA was 
purified essentially as described in the kit protocol. 
 
3.1.4 DNA precipitation 
 
          The seeDNA™ co-precipitant for RNA and DNA kit (Amersham Pharmacia 
Biotech) was used for nucleic acid precipitation of restriction digests and ligation 
reactions prior to transformation. The precipitation was done as described in the protocol, 
using the reagents supplied in the kit, except from ethanol. Briefly, 2 μl of uniform 
seeDNA suspension and 0.1 volumes of 3 M sodium acetate, pH 5.2, were added to the 
DNA and mixed briefly. Then 2 volumes of 95% ethanol was added, vortexed 5-10 sec. 
and incubated at room temperature (RT) for 2 min. The sample was centrifuged at 14000 
xg for 5 min, supernatant (SN) was removed and a pink pellet was observed. The pellet 
was rinsed in 500 μl 70% (v/v) ethanol, followed by a brief vortex, and centrifuged as 
50 
  
                                                                               




above. The pink pellet was resuspended in dH2O.     
 
3.1.5 Restriction enzyme digestion of DNA 
 
          Restriction enzyme digestion of DNA was performed according to the specific 
conditions required for the individual restriction enzymes (e.g. buffer, BSA and 
temperature). The reactions were incubated for at least two hours at the recommended 
temperature. All restriction enzymes and buffers were from New England BioLabs (NEB, 
Beverly, MA).   
 
3.1.6 Bacterial transformation 
 
3.1.6.1 Transformation by electroporation 
 
          Bacterial transformations were performed with electrocompetent XL1-blue 
Escherichia Coli (E. coli) cells (Stratagene, La jolla, CA) E. coli cells (Stratagene), 
essentially as described in Molecular Cloning (Sambrook et al., 2001) and BIO-Rad 
Genepulser™ electroporation manual. Briefly, 50 μl cells were thawed on ice. A portion 
of 2 μl SeeDNA precipitated (1.1.4) ligation mixture was added, and the cells were 
incubated on ice. The transformation mixture was then pulsed in an ice-cold 0.1cm gap 
electroporation BTX Disposable Cuvette P/N (BTX Inc., Hawthorne, NY). The Gene-
pulser™ apparatus (BTX Inc.) was used with the following settings: 25 μF, 200 Ω and 
1.30 kV. After electroporation, 1 ml of 2 xYT medium was added to the cuvette and 
transferred to an Eppendorf tube (Eppendorf AG, Hamburg, Germany) for incubation at 
37°C for 1 hour (h). The cells were plated on agar plates containing 100 mg/ml ampicillin 






                                                                               




3.1.6.2 Transformation of CaCl2 competent Top10F E.coli cells 
 
           The CaCl2 competent Top10F E.coli cells were thawed on ice. 300 µl cells were 
added to each tube with SeeDNA precipitated (1.1.4) ligation mixture and incubated on 
ice for 45 min. The cells were then exposed to heat-shock by incubating at 42ºC for 2 
min. 1 ml 1x LB medium was added to the cells and further incubated at 37ºC for 60 min.  
The cells, then centrifuged at 4000 rpm for 4 min at RT. The supernatant was discarded 
and the pellet was resuspended in the remaining medium and plated on agar plates 
containing 100 mg/ml ampicillin and incubated over night (ON) at 37°C. The resulting 




        Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
carried out according to general protocol. Briefly, gel apparatus was assembled and the 
Criterion XT™ Precast Gel (4-12% Bis-Tris or 4-15% Tris-HCl; Bio-Rad Laboratories, 
Alfred Nobel Drive, Hercules, CA) was placed in the tank that was filled with Running 
buffer (144 g/l glycine, 36.3 g/l and 10% SDS or XT MOPS running buffer, 1x; 
PIERCE). The comb was removed and the wells in the stacking gel were rinsed with 
running buffer. Protein samples and molecular weight standard were mixed with loading 
buffer (Tris-HCl, SDS, DTT, glycerol and bromophenol blue) and applied to the wells 
and electrophoresed for 1 h and 40 min at 100v. 
 
3.1.8 Agarose gel electrophoresis 
 
          Depending on the size of the DNA fragments to be separated, 1-2 % agarose gels 
were prepared. Analytic as well as preparative gels containing agarose (Sigma, St. Louis, 
MO) were dissolved in 50 μl 1x TAE buffer (40 mM Tris-acetate, 1 mM EDTA) and 1 
μg/ml ethidium bromide. 6 x SB was added to each sample before electrophoresis. Gel 
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electrophoresis was carried out in 1x TAE buffer at 90-100 V/250 mA. DNA was 
visualized by exposure to UV-light and compared with lamda HindΙΙΙ or phix174 size 
markers (New England Bio Labs). 
3.1.9 Purification of PCR products 
          Products from the polymerase chain reactions (PCR) were purified using the 
QIAquick PCR Purification Kit (QIAGEN, Hilden, Germany), which is based on 
adsorption of DNA to silica particles in the presence of high salt concentration. The 
purification was performed according to the QIAGEN manual with using the reagents 
supplied with the kit. 
3.1.10 Extraction of DNA from agarose gel 
 
          DNA fragments were separated by agarose gel electrophoresis and purified using 
the QIAquick Gel Extraction Kit (QIAGEN), which is based on solubilization of agarose 
and selective adsorption of DNA to silica particles in the presence of high salt 
concentration. The purification was performed according to the QIAGEN manual using 
the reagents supplied with the kit. 
 
3.1.11 Modification of DNA ends  
 
         Calf intestinal phosphatase (CIP) (Finnzymes, Espoo, Finland) was used to remove    
phosphate residues from the 5´ protruding ends of the linearized vector in order to reduce 
the background due to religation of the vector. 0.5 units CIP/pmol DNA ends were added 
to restriction enzyme digestion mixture, which include a specific CIP buffer (Finnzymes), 
for at least 1 h. The reaction was inactivated by heating to 75°C for 10 min in the 






                                                                               




3.1.12 Ligation of DNA fragments 
 
         Appropriate amounts of insert and vector fragments were added to 2 μl of 10x 
ligation buffer (Roche Diagnostics, GmbH, Mannheim, Germany) and 1 μl of T4 Ligase 
(Roche Diagnostics). The ligation reaction volume was adjusted to 20 μl with dH2O. The 
ligation reaction was allowed to occur ON at RT or at 20°C, before heat inactivation at 
65°C for 20 min. All ligations were performed as described above. 
3.2 Cells 
      The adherent human hepatocarcinoma cell lines Hep-3B and Hep-G2 (Gift from 
Trond Berg; IMBV, University of Oslo. Norway) were maintained in Dulbecco modified 
eagle medium (DMEM) (BioWhittaker, Belgium), supplemented with 4 mM L-
glutamine, 100 U/ml penicillin (PS; Integro, The Netherlands), 0.1 mM nonessential 
aminoacids (NEAA), and 10 % foetal calf serum (FCS; Integro). The human monocytic 
cell lines U937, THP-1 and K-562 (American Type Cultur Collection, Manassas, VA, 
USA) were maintained in RPMI 1640 (BioWhittaker), supplemented with 100 U/ml PS 
and 10 % FCS. All reagents were from Gibco (BRL, Paisley, Scotland). Madin-Darby 
Canine Kidney (MDCK) cells stably transfected with hβ2m was established by Julie Dee 
Qian (IMBV, University of Oslo, Norway) and maintained in Dulbecco modified eagle 
medium (DMEM), supplemented with 4 mM L-glutamine, 100 U/ml penicillin, and 10 % 
FCS. Hybridoma cell line expressing anti-FcRn mouse monoclonal antibody 1G3 was 
obtained from ATCC (American Type Cultur Collection, Manassas, VA, USA) and 
cultured according to the supplier’s protocol. Briefly, cells were plated at a seeding 
density of 120,000 cells/cm2 in a 75-cm2 flask, and cultures were maintained in a 
humidified atmosphere (5% CO2-95% air) at 37ºC with HL-1 medium (BioWhittaker, 
Walkersville, MD, USA) supplemented with 4 mM L-glutamine (Invitrogen), 1 mM 
sodium pyruvate (Invitrogen), and 1% FCS (Invitrogen), and the cells were further 
cultured to confluency. The supernatant was harvested and IgG was purified (1.12)  
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3.3 Cell lysate preparation 
 
       Total cell lysate was made by using CelLytic M cell lysis Reagent (Sigma, Saint 
Louis, USA) together with protease inhibitor cocktail (Sigma) as described in the general 
protocol. Briefly, approximately 8-10 x 106 cells were washed by centrifugation at 1200 
rpm for 5 min. Pelleted cells were resuspended in 700 µl CelLytic M reagent with 30 µl 
protease inhibitor cocktail and incubated on a shaker for 15 min. The lysed cells were 
centrifuged for 15 min at 4000 rpm to remove cellular debris. Then, supernatant collected 
was stored at -70ºC until use.  
 
3.4 BCA Protein Assay (Quantification of total protein in cell lysates) 
 
      The total protein in lysate (1.3) was quantified using the BCA™ protein assay Kit 
(PIERCE, Meridian Road Rockford, USA) according to the manufacturer’s protocol. 
Briefly, BCA™ Working Reagent was prepared by mixing Reagent A with Reagent B in 
a 50:1 ratio, and 25 µl duplicates of diluted lysates were incubated with 200 µl Working 
Reagent at 37 ºC for 30 min. After cooling the plate to room temperature (RT), the 
absorbance was measured at 570 nm on a VICTOR™ 1420 Multilabel counter 
(PerkinElmer Life Sciences, Welleslay, MA, USA). Standard curves were prepared from 
a series of dilutions of bovine serum albumin (BSA) ranging from 20-2000 µg/ml. 
 
3.5 Total RNA isolation 
 
          The total RNA was harvested using the method described by Absolutely RNA 
Miniprep Kit (Stratagene). Briefly, 600 µl lysis buffer was added to 5-6 x 106 pelleted 
cells, mixed and vortexed. The lysate was filtered by passing through filter spin cup that 
were seated in receptacle tube. The filtrate retained was mixed with equal volume of 70% 
ethanol, and 700 µl of the mixture transferred to RNA-binding spin cups seated in 
receptacle tubes. The spin cups retained and washed with low salt wash buffer and treated 
with 5 µl of Rnase-free DNaseΙ mixed with 50 µl DNase digestion buffer by incubating 
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at 37ºC for 15 min. The spin cups were washed with high and low salt wash buffer in 
succession. The RNA eluted using elution buffer. The extracted total RNA was quantified 
by ND-1000 spectrophotometer at 260 nm (NanoDrop Technologies, Wilmington, DE, 
USA).  
 
3.6 cDNA synthesis 
 
       For cDNA synthesis 2 µg of total RNA was subjected to reverse transcription (RT) 
reaction using Superscript ΙΙ reverse transcriptase (Invitrogen), and anchored Oligo 
(dT)20 primer (Invitogen). The samples were denatured at 95ºC for 5 min in order to 
remove secondary structure of RNA prior to addition of RTase (Invitrogen), followed by 
further by incubations at 25ºC for 10 min, 42ºC for 60 min, 70ºC for 5 min and finally 
4ºC for 2 min. The yielded first-stranded cDNA was stored at -70ºC until use. 
 
3.7 Polymerase chain reaction (PCR) for amplication of hFcRn transcripts 
 
       Aliquots of cDNA were subjected to PCR reaction using primers (Table 1) specific 
to the transmembrane hFcRn (TM-hFcRn; FcRnforwnew and FcRnrevnew) and hβ2m 
(β2mforw2 and β2mrev). These were designed based on published sequences of TM-
hFcRn (1098 bp, GeneBank, NM 004107) and hβ2m (360 bp, GeneBank, NM 004048). 
All primers were from Medprobe (Eurogenetic, San Diego, USA). The melting 
temperatures were estimated using the formula Tm= 2(A+T) + 4(G+C). Each PCR 
reaction was performed in a final volume of 50 µl with 0.5 µl of high fidelity Phusion 
DNA polymerase (Finnzymes, Finland) 0.02 µM of each primer using Thermal cycler 
(Eppendorf Mastercycler® Gradient). PCR reaction procedures commenced with a 
denaturation at 95ºC for 5 min followed by amplification with a total of 35 cycles at 95ºC 
for 2 min, 68ºC for 2 min and 72ºC 10 min. The samples from each PCR products were 
electrophoresed on 2% agarose gel and were examined with respect to phix174 DNA 
ladder (1.1.7). Negative controls were samples reaction omitting either or both cDNA and 
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primers were also prepared. The housekeeping gene for glyceraldehyde-3- phosphate 
dehydrogenase (GAPDH) was amplified as described (M. Sporstol, 2007). 
 
3.8 Cloning of sequence encoding TM-hFcRn and hβ2m 
  
       The amplified TM-hFcRn cDNA was digested (1.1.5) with XhoΙ (NEB) and EcoRI 
(NEB), purified (1.1.10) and cloned as a 1098 bp fragment into the polylinker of 
pcDNA3-FcRn-GST.Pcmv-beta2m-polyA. This gave rise to pcDNA3-(TM-hFcRn)-
GST.Pcmv-beta2m-polyA vector. The PCR product for hβ2m was digested (1.1.5) with 
restriction enzymes HindΙΙΙ and XbaΙ, purified (1.1.10) and cloned as a 360 bp fragment 
into pcDNA3-GST on HindIII (NEB) and XbaI (NEB) sites. This gave rise to the 
pcDNA3-hβ2m vector.  
 
3.9 Subcloning of the sequence encoding TM-hFcRn into fluorescent vectors 
 
          The vector pcDNA3-(TM-hFcRn)-GST.Pcmv-beta2m-polyA (1.8) was used as a 
template for amplication by PCR of TM-hFcRn cDNA (1.7) with primers GFPforw and 
NewFPVrev (Table 2). The PCR product was digested using XhoI and EcoRI (1.1.5) and 
subcloned in N-terminal fusion of the genes of the fluorescent proteins in pEGFP-N1, 
pECFP-N1, pERFP-N1 and pEYFP-N1). This gave rise to pTM-hFcRn-EGFP-N1, pTM-











                                                                               




Table 1. Primers used for amplication of TM-hFcRn  and hβ2m:      
                                                                                                                                                                              




FcRnforwnew:      5’ ATTGAATTCaATGGGGGTCCCGCGGCCTCAG 3’ 
FcRnrevnew:         5’ ATTCTCGAGTCAbGGCGGTGGCTGGAATCACATTTAC 3’ 
β2mforw2:             5´-TCC AAG CTTGGC GGG-3´ 
β2mrev:                  5´-GTT CTT GAACCT CCA-3´ 
 
 
a: The restriction sites are bold. 
b: Stop codon is underlined 
 
 
Table 2. Primers used for construction of the pFcRn-EGFP-N1, pFcRn-ECFP-N1, 
pFcRn-ERFP-N1 and pFcRn-EYFP-N1 vectors:  
     
                                                                                                                                                                                            
Sequence                                   Primer            
 
 
GFPforw:                   5’ ATTCTCGAGaATGGGGGTCCCGCG 3’ 
                        
NewFPVrev:             5’ATTGAATTCCGGCGGTGGCGTGGAATCACATTTAC 3’  
 
 
a: The restriction sites are bold 
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3.10 Transient transfection of MDCK cells expressing hβ2m with fluorescent protein 
vectors  
          All constructs were transiently transfected using the LIPO-FECTAMINE™ method 
(Invitrogen). The day before transfection, the cells were trypsinized (BioWhittaker) and 
counted. 4x 105 MDCK cells per ml were plated in a 12 wells plate with microscope 
cover slip placed in the center. The day after, the cells were 70-80% confluent. A portion 
of 10 μg DNA was added to 500 μl medium without serum (OPTI-MEM) for each bottle 
to be transfected. 20 μl LF2000 Reagent (Invitrogen) was diluted into 500 μl medium 
without serum and incubated for 5 min at RT. Diluted LF2000 was combined with the 
diluted DNA and incubated at RT for 20 min to allow DNA-LF2000 to form. The 
complexes were added directly to each 12 wells plate and mixed with the cells before 
incubation at 37°C in a CO2 incubator. After 24 h cells washed, fixed, Hoechst (Sigma) 
stained (for nuclear staining) and mounted on microscope slides for examination with 
Confocal microscope.  
3.11 Anti-hFcRn production  
        Recombinant soluble human FcRn (shFcRn) or the hFcRn heavy chain only 
(Andersen et al, 2007, document submitted) was used for goat immunization. The 
immunization and antisera collection were made in collaboration with T. E. Michaelsen 
(Norwegian Public Health Institute, Norway). Briefly, goats were immunized 
subcutaneously with 50 μg purified shFcRn or only the hFcRn heavy chain in 500 μl PBS 
pH 7.3 mixed with 750 μl Freund Complete Adjuvant  (Difco, Detroit USA). On day 11 
after immunization a booster dose (50 μg) was given with Freund Incomplete Adjuvant 
(Difco, Detroit, USA), which was repeated 24 days later. After additional four weeks, the 
goats were bled regularly every second week. Two additional booster doses (50 μg) with 
Freund Incomplete Adjuvant were given six and fourteen weeks after the third 
immunization. The collected and pooled anti-FcRn goat sera were filtered prior to 
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3.12 Anti-hFcRn purification 
         Purification of polyclonal anti-hFcRn antibody from goat sera or mouse hybridoma 
cell culture supernatant (mAb 1G3) was performed using HiTrap protein G HP, 5 ml 
column (GE Healthcare Bio-Sciences AB Uppsala, Sweden) or a hFcRn heavy chain 
coupled affinity matrix (Andersen et al, unpublished). The protein G purification was 
performed as described in the manual. The column was connected to AKTA™ 
chromatography system (Bio-Rad, BioLogic LP). The column was cleaned with elution 
buffer (0.1 M glycine-Hcl pH 2.7) and then equilibrated by washing with 10 column 
volumes of binding buffer (20 mM sodium phosphate pH 7.0). Equal volume of filtered 
(0.45 µm; Numbrecht, Germany) sample and binding buffer were mixed and loaded to 
the system. The flow through was collected. The column was washed with 5-10 column 
volume of binding buffer or until no material appears in the effluent. The wash fractions 
were collected. The sample was eluted with 2 to 5 column volumes of elution buffer (0.1 
M glycine-HCl) in collection tubes containing neutralizing buffer (1M Tris-Hcl, pH 9.0). 
The column was re-equilibrated with binding buffer.  
        The purity of the eluates was analysed on SDS-PAGE (1.1.7) and upconcentrated 
using Amicon Centricon Plus-20 (YM-100) Centrifugal Filter Devices (Millipore 
Corporation Bedford, MA, USA) for concentration and purification. The final 
concentration was estimated using ND-1000 spectrophotometer at 280 nm (NanoDrop 
Technologies, Wilmington, DE, USA).  Antibodies (~3 mg/ml) were biotinylated using 1 
mg/ml biotin N-hydroxysuccinimide ester (Sigma), and incubated on rotator for 4 h at RT 
followed by 4°C ON. The mixture was then spun through a centricon YM-10 (Millipore) 
five times to remove un-conjugated NHS-biotin (J.T. Andersen, IMBV, UIO, Norway). 
 
3.13 Anti-hFcRn analysis by ELISA  
  
      The 96-Wells plate (Nunc, Denmark) was coated with 2 µg/ml of shFcRn (Andersen 
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et al, 2007 submitted) or 2 µg/ml of hβ2m (Abcam, Cambridge, UK) and stored at 4º ON. 
As a blocking solution, 2% dry skim milk (Accumedia Manufacturers Inc.Lansing, MI, 
USA) /1x PBS (Skm/PBS) was added to the coated wells at RT for 1h. The purified 
polyclonal anti-hFcRn (1.12) diluted (1:100, 1:1000, 1:10000) in 2% Skm/ PBS was 
added to the wells and incubated at RT for 1 h. The wells were washed four times with 1x 
PBS supplemented with Tween 20 (PBST). Wells were then incubated for 1 h at RT with 
a horseradish peroxidase (HRP) conjugated protein G (1:3000; Calbiochem, San Diego, 
CA, USA). Wells were washed four times with PBST before 100 µl of the substrate 2,2’-
azino-bis 3-etylbenzthiazoline-6-sulfonic acid (ABTS; Sigma) in 2 mM citric acid, pH 4, 
diammonium salt (Sigma) containng 0,2% H2O2 was added (ABTS/ H2O2). The colour 
reaction was measured by absorbance at 405 nm on a Sunrise TECAN spectrophotometer 
(TECAN Maennedorf, Switzerland). The schematic representation is shown in figure 3. 
 
3.14 Detection of intact hFcRn in cell lysate by ELISA 
       The 96-Wells plate (Amersham Pharmacia Biotech) was coated with 50-100 µg/ml  
described in (1.13). 
HRP HRP 
        Plate coated with shFcRn 
       or β2m or cell lysate lysate 
Goat anti-hFcRn 
       Protein G HRP conjugate,   
           (1:3000) 
Substrate (ABTS) 
 
     
Figure 3. Detection of hFcRn binding by anti-hFcRn. Wells were coated with shFcRn, 
hβ2m or total protein in lysate at 4°C ON, then washed and incubated with anti-hFcRn 






                                                                               




3.15 Western immunoblotting dectetion of FcRn expression  
 
          Normalized cell lysate (1.4) with 40-50 µg total protein was reduced in 2 µl of 
dithiohreitol (DTT; Sigma) electrophoresed through a 12% SDS-PAGE (1.1.7). Proteins 
were blotted from the gels onto a Polyvinylidene fluoride (PVDF) membrane (Millipore 
Corporation Bedford, USA) in Tris/glycine buffer (25 mM Tris and 192 mM glycine, 
20% methanol, pH 8.3) at 25V for 35 min. The membrane was blocked in 4% Skm /PBS 
for 1 h at RT. After blocking, membrane was washed in Skm/PBS three times for 5 min 
on shaking and probed with polyclonal goat anti-hFcRn (1.12) diluted 1:1000 in 4% 
Skm/PBS, and anti-hβ2m from rabbit (1:5000; Sigma) at RT for 1 h. Then, membrane 
was washed five times for 5 min with PBST. The HRP-conjugated mouse monoclonal 
antibody (1:5000; Sigma) or the HRP-conjugated anti-rabbit antibody diluted 1:5000 
(from donkey; Amersham Pharmacia Biotech) were added and incubated at RT for 1 h. 
The membrane was washed five times for 5 min before the membrane was treated with 
SuperSignal West pico Lumino/Enhancer and stable peroxidase solutions (PIERCE). The 
treated membrane was detected on Kodak film using Optimax x-ray film processor 
(Protec medizintechnik GmbH co. KG, Germany). 
 
3.16 pH dependent IgG-FcRn binding assay on lysates  
 
         100 µl hIgG coupled sepharose (Amersham Biosciences) was placed in eppendorf 
tubes and calibrated with 1ml sodium/potassium phosphate buffer with pH 5.5 (buffer 
5.5) or pH 7.4 (buffer 7.4) on rotation for 10 min, centrifuged at 10, 000 rpm for 5 min 
and  repeated three times. 400-600 µg of total protein in lysate (1.3) and 1ml buffer with 
pH 5.5 or pH 7.4 was mixed and pH was checked with pH-indicator strips (Merck KGaA, 
Darmstadt, Germany). Lysates were then added to the sepharose-hIgG and incubated in 
buffer with 5.5 or 7.4 ON at 4ºC. The mixtures were washed three times for 10min on 
rotation with centrifugation in between in one ml buffer with pH 5.5 or pH 7.4. The 
bound proteins were eluted with sodium/potassium phosphate with pH 8. Western 
immunoblotting analysis was made on eluted fractions as described (1.15). 
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3.17 Isolation of peripheral blood mononuclear cells (PBMC) 
 
        Blood was collected in tubes with heparin from a volunteer. Peripheral blood 
mononuclear cells (PBMC) were isolated by means of a density gradient centrifugation 
technique in which Lymphoprep™ (NYCOMED PHARMA AS, Oslo Norway) was used 
as a gradient medium. Briefly, 10 ml of 1x PBS pipetted to each of the centrifuge tube 
containing 10 ml blood. 5 ml of blood/PBS poured down to 5 ml Lymphoprep placed at 
the bottom of the tube and centrifuged at 2000 rpm for 20 min at 20ºC without brake.  
The PBMC located in the interphase collected using a Pasteur pipette and transferred to 
centrifuge tube. Equal volume of PBS was added and centrifuged at 1700 rpm for 5 min 
at 4ºC with brake three times. Then, the cells were counted using a hemocytometer. 
 
3.18 Assessment of expression of FcγRΙ, FcγRΙΙ and FcγRΙΙΙ by Flow cymetry 
 
        For each staining, 2 x 106 cells were washed three times with 1x PBS, and added to 
96-wells plates (Nunc). Cells were blocked with 2% bovine serum albumin (BSA; 
Sigma) in PBS (BSA/PBS) for 1h, washed by centrifugation at 800 rpm three times for 5 
min with PBS/BSA. The cells were stained with Fluorescein Isothiocyanate (FITC) 
conjugated mouse anti-human CD64 antibody (Serotec Ltd, Oxford, UK), anti-human 
CD32 antibody (BD Pharmingen, Franklin lakes, NJ, USA) and detected by goat anti-
mouse FITC (CALTAG Laboratories, Burlingame, California, USA), and with 
biotinylated mouse anti-CD16 monoclonal antibody (Abcam) followed by streptavidin 
FITC (DakoCytomation Ltd., cambridgeshire, UK). Finally, the stained cells were fixed 
by treating with 3 % paraformaldeyde (PFA; Fluka) for 30 min. 
 
3.19 Analysis of surface and intracellular expression of FcRn by Flow cytometry  
 
          For each staining, approximately 2 x 106 cells were washed three times with 1x 
PBS, and added to 96-wells plates (Nunc). Cells were blocked with 2% BSA/PBS for 1 h, 
washed by centrifugation at 800 rpm three times for 5 min with PBS/BSA. Cells were 
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incubated for 1 h with biotinylated polyclonal anti-hFcRn, isotype control goat IgG (Gift 
from T. M. Michalesen) diluted 1:100 in 2% BSA/PBS or the 1G3 monoclonal anti-FcRn  
(1.12) diluted 1:50 in 2% BSA/PBS. The cells were washed and centrifugated at 800 rpm 
three times for 5min with 2% PBS/BSA. Cells incubated for 1 h with streptavidin-FITC 
or anti-mouse IgG F(ab’)2 FITC produced in goat (Sigma) diluted 1:200 in 2% BSA/PBS, 
washed by centrifugation at 800 rpm three times for 5 min with 2% PBS/BSA. All 
staining was conducted at 4ºC and also were fixed with 3% PFA for 30 min. For 
intracellular staining, the cells were permeabilized by treatment with 0.5% saponin 
(Sigma) for 30 min and stained as above.    
 
 3.20. Surface plasmon resonance analyses 
 
         Surface plasmon resonance experiments were carried out using a Biacore 3000 
(Biacore AB, Uppsala, Sweden). Flow cells of CM5 sensor chips were coupled with 
shFcRn (~800 RU) using amine coupling chemistry all as described in the protocol 
provided by the manufacturer. The coupling was performed by injecting 10 μg/ml of the 
protein in 10 mM sodium acetate, pH 5.0 (Biacore AB). For all binding experiments the 
phosphate buffer (67 mM phosphate buffer, 0.15 M NaCl, 0.005 % Tween20) at pH 5.5 
was used as running buffer as well as dilution buffer. Injection of 15 μg/ml FITC 
conjugated human IgG (hIgG) (Sigma) or 268 μg/ml FITC-conjugated HSA (Sigma) was 
performed at 10 μl/min at 25°C.  
 
3.21 Analysis of pH dependent FcRn-IgG/HSA binding by Flow cytometry.      
         
        For each staining, 2 x 106 cells were washed with 1x PBS three times and added to 
96-wells plates (Nunc) and fixed by treating with 3% PFA for 30 min. The cells were 
washed by centrifugation at 800 rpm with buffer pH 5.5 or 7.4. Then, the cells were 
incubated for 1 h with blocking solution (0.5% Skm milk in buffer pH 5.5 or 7.4) and pH 
was checked using pH-indicator strips (Merck). The cells washed further with 
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corresponding buffers and then incubated with hIgG-FITC (10-100 µg/ml; Sigma) or 
HSA-FITC (15-100 µg/ml; Sigma), and mF(ab’)2 fragment-FITC (Sigma) or mIgG2a-
FITC (Sigma) were used as controls for 1 h. Double staining was carried out using hIgG-
FITC (10-100 µg/ml) and HSA-FITC (15-100 µg/ml) at the same time. Inhibition 
analysis with polyclonal anti-hFcRn (1.12), unconjugated hIgG (Aventis Behring GmbH, 
Marburg, Germany), HSA (Sigma) or protein G from Streptococcus species (Fluka, 
Buchs, Switzerland) was performed. The cells were then washed and analysed with Flow 
cytometry using buffer pH 5.5 or 7.4.  
 
 3.22 Flow cytometric analysis of the effect of anti-inflammatory drugs on FcRn 
expression 
 
        Approximately, 6 x 105-7 x 105 cells were treated with 10 nM-1000 nM of 
corticosterone, prednisolone, beclomethasone dipropionate, and thyroxine (all from 
Sigma) in corresponding growth media. After 3 days, 2 x 106 cells were stained as 













                                                                               






4.1 Generation and functional testing of hFcRn preparations 
 
     To produce an hFcRn specific antiserum, goats were selected for immunization due to 
previous studies that clearly demonstrate highly stringent binding specificity of hFcRn 
with no detectable binding to goat/sheep IgG Fc (24). In addition, goat IgG subclasses 
have low or no binding affinity for other human Fcγ-receptors. Immunizations were made 
with intact shFcRn and isolated hFcRn heavy chains. Goat antisera were produced and 
purified as described in materials and methods. Protein G purified preparations were 
analysed by non-reducing SDS-PAGE (Fig. 1A). As expected, the goat IgG migrated as 
bands corresponding to ~150 kDa. To test the functional integrity of purified anti-hFcRn 
preparations, an ELISA was performed with coating of shFcRn followed by serial 
dilutions of the preparations. Figure 1 shows that antibodies from goat immunized with 
intact shFcRn reacted towards both intact shFcRn (G2448; Fig. 1B) and the hβ2m subunit 
(G2448; Fig. 1C). In contrast, those with the hFcRn heavy chain only reacted with intact 
shFcRn (G3231; Fig.1D) but not hβ2m (G3231; Fig.1E). The antibody preparations were 
further purified on FcRn heavy chain coupled affinity matrix. 
                                                                                       










                                                                               





















Figure 1. Analyses of anti-FcRn antibody preparations. (A) Non-reducing 12% SDS-
PAGE analysis of antibody fractions eluted from the protein G column. Lane 1 
corresponds to G2248. Lane 2 corresponds to G3231. The molecular size is indicated by 
an arrow. ELISA on antibody preparations from goat immunized with intact shFcRn 
tested against shFcRn (B) and hβ2m (C). ELISA on antibody preparations from goat 
immunized with only the hFcRn heavy chain tested against shFcRn (D) and hβ2m (E). 
Tap 0 samples are taken from pre-immunized goats. Tap 1-7 samples are taken post 






                                                                               
                                                                                                                                   
  
4.2 Expression of FcRn and Fcγ receptors on human monocytic cell lines  
 
        To determine the expression profile of FcRn in human immune cells, we examined 
three human monocytic cell lines (U-937, THP-1, and K-562). Flow cytometric analyses 
were performed using the purified polyclonal anti-FcRn preparation (G3231). The 
histograms in figure 2 reveal the expression of hFcRn on the cell surface of all three cell 
lines (Fig. 2A, C and E). In addition, the total expression was determined after saponin 
treatment (Fig. 2B, D and F). The FcRn expression was also confirmed using a 
commercial available anti-FcRn monoclonal (1G3) antibody (data not shown). These 
results are in agreement with previous reports showing FcRn expression in monocytic U-
937 and THP-1 cell lines (30, 31). Our data for the first timeshow FcRn expression on the 
K-562 cell line.  
        To explore functional binding of IgG to surface expressed hFcRn, the expression 
profiles of classical Fcγ receptors have to be assessed. The monocytic cell lines were 
stained with specific antibodies and analyses by flow cytometry. The data obtained show 
expression of FcγRI (Fig. 3A, D and G) and FcγRII (Fig. 3B, E and H), but no evidence 





                                                                               








Figure 2. Expression and cellular distribution of FcRn in human monocytic cell 
lines.   Cells were stained with biotinylated anti-FcRn followed by streptavdin-FITC and 
analysed by flow cytometry. U-937 cells surface stained (A) and total (B).  THP-1 cells 
surface stained (C) and total (D). K-562 cells surface stained (E) and total (F). FcRn 
expression is shown as gray filled histograms, streptavidin-FITC and isotype 
(biotinylated goat IgG) controls as unfilled histograms. Histograms are given with 
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Figure 3. Expression of Fcγ receptors. Cells were stained with monoclonal antibodies 
towards each Fcγ receptor as described in material and methods. U-937 cells surface 
stained for FcγRI, FcγRII and FcγRIII (A, B and C). THP-1 cells surface stained for 
FcγRI, FcγRII and FcγRIII (E, F and G). K-562 cells surface stained for FcγRI, FcγRII 
and FcγRIII (G, H and I). Fcγ receptors are shown as gray filled histograms and controls 
(isotype and secondary antibodies) as unfilled histograms. Histograms are given with 
ordinate indicating number of cells and abscissa indicating the fluorescence intensity. 
 
4.3 pH dependent binding of IgG and HSA to human monocytic cell lines  
 
        Initially, the functional integrity of FITC conjugated hIgG and HSA were tested by 
surface plasmon resonance. Recombinant shFcRn was immobilized on CM5 sensor chips 
by amine coupling. Representative sensorgrams show that IgG-FITC and HSA-FITC 
bind FcRn in a pH dependent manner, binding at pH 6.0 and release at pH 7.4 (Appendix 
A). 
        To investigate the functional binding of these ligands, we continued using the U-937 
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cell line. A pH dependent cell binding assay was established where fixed cells were 
stained with IgG-FITC or HSA-FITC at pH 5.5 and pH 7.4 followed by flow cytometry , 
all as described in material and methods. Figures 4A-B show the binding of the ligands 
expressed as mean fluorescence intensity (MFI) at pH 5.5 and pH 7.4. Increased binding 
of IgG-FITC (Fig. 4A) and HSA-FITC (Fig. 4B) were observed at acidic pH compared to 
pH 7.4, which supports functional binding to FcRn. In contrast, the Fc removed F(ab’)2 
fragment and mIgG2a did not bind (Fig. 4A). Furthermore, labelled hIgG pre-incubated 
with Streptococcus protein G showed reduced binding (Fig. 4A). These data are in 
agreement with an IgG Fc-mediated interaction and a stringent discrimination of mIgG as 
reported by others (25, 24).  
        To assess the contribution of FcRn in the increased binding of IgG and HSA shown 
at acidic pH, inhibition studies were performed with pre-incubation of cells with 
unlabelled hIgG and HSA. Figures 5A-B clearly show decreased binding of IgG-FITC 
and HSA-FITC in the presence of IgG and HSA at pH 5.5. Furthermore, the polyclonal 
anti-FcRn has been shown to block the interactions sites of IgG and HSA on hFcRn 
(Andersen et al., unpublished). Importantly, we here demonstrate that pre-incubation of 
cells with the anti-FcRn preparation dramatically decreased binding of IgG as well as 
HSA (Fig.5). Thus, the data presented strongly support functional and pH dependent 
binding to hFcRn. In addition, this is the first report showing pH dependent binding of 
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Figure 4. FcRn ligands binding to monocytic U-937 cells. (A) Binding of hIgG, 
F(ab’)2 and mIgG2a to U-937 cells at pH 5.5 and at pH 7.4. (B) Binding of HSA at pH 
5.5 and pH 7.4. The binding is expressed as mean fluorescence intensity (MFI). The 
experiments were repeated with similar results. 
 
  
        To determine whether hIgG and HSA bind to membrane-bound hFcRn   
independently of each other, we functionally stained cells with IgG-FITC and HSA-FITC 
simultaneously at acidic pH. Figure 6 shows that simultaneous staining gave an additive 
binding affect compared with individual staining, which may indicate that both ligands 
bind simultaneously to hFcRn. These data are in agreement with biochemical studies 
performed on recombinant soluble molecules (26, 28, 29). Taken together, the results 
suggest that both IgG and HSA bind membrane-bound hFcRn and that the increased 
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 Figure 5. hFcRn-ligand inhibition analysis on U-937 cells. (A) Pre-incubation of U-
937 cells with unlabelled hIgG, polyclonal anti-FcRn and protein G blocked the hIgG-
FITC binding. (B) Pre-incubation of U-937 cells with unlabelled HSA and polyclonal 
anti-FcRn Ab blocked the HSA-FITC binding. The binding is expressed as mean 












Figure 6. The hIgG and HSA bind to membrane bound hFcRn independently of 
each other. U-937 cells were surface stained with HSA-FITC and hIgG-FITC 
simultaneously. HSA-FITC, hIgG-FITC and together are shown as white, gray and black 
filled histograms, respectively. Histograms are given with ordinate indicating number of 






                                                                               




4.4 Expression of FcRn and Fcγ receptors on peripheral blood mononuclear cells 
 
        To extend the observations with human monocytic cell lines to primary immune 
cells, we isolated PBMCs and performed flow cytometry to determine FcRn expression. 
We found that these cells express FcRn as showed both on cell surface (Fig.7A) and total 
(Fig.7B). In addition, the expression profiles of classical Fcγ receptors were assessed. 
The PBMCs were stained with monoclonal antibodies and analysed by flow cytometry. 
The data obtained show expression of FcγRI (Fig. 8A) and FcγRII (Fig. 8B) but no 




Figure 7. Expression and cellular distribution of FcRn in PBMCs. Cells were stained 
with biotinylated anti-FcRn followed by streptavdin-FITC and analysed by flow 
cytometry. PBMCs surface stained (A) and total (B). FcRn expression is shown as gray 
filled histograms, streptavidin-FITC and isotype (biotinylated goat IgG) controls as 
unfilled histograms. Histograms are given with ordinate indicating number of cells and 












                                                                               






Figure 8. Expression of Fcγ receptors. Cells were stained with monoclonal antibodies 
towards each Fcγ receptor as described in material and methods. PBMCs surface stained 
for FcγRI, FcγRII and FcγRIII (A, B and C). Fcγ receptors are shown as gray filled 
histograms and controls (isotype and secondary antibodies) as unfilled histograms. 




        To investigate the functional binding of IgG and HSA, the pH dependent cell 
binding assay was used. Figures 9A and 9C show binding of the ligands expressed as 
mean fluorescence intensity (MFI) at pH 5.5 and pH 7.4. Increased binding of IgG-FITC 
(Fig. 9A) and HSA-FITC (Fig. 9C) was observed at acidic pH compared to pH 7.4. In 
addition, labelled hIgG pre-incubated with Streptococcus protein G reduced IgG-FITC 
binding, clearly demonstrating Fc mediated binding at pH 5.5 (Fig. 9B). Furthermore, 
pre-incubation of PBMCs with the anti-FcRn preparation shows great impact on the pH 
dependent binding of both IgG (Fig. 9A) and HSA (Fig. 9C). Importantly, irrelevant goat 









                                                                               




     

















Figure 9. hFcRn-ligand inhibition analysis on PBMCs. (A) Binding of IgG-FITC 
alone or in the presence of goat IgG or polyclonal anti-FcRn followed by hIgG-FITC at 
pH 7.4 and pH 5.5. (B) Binding of IgG-FITC and IgG-FITC pre-incubated with 
Streptococcus protein G. (C) Binding of HSA-FITC alone or in the presence of goat IgG 
or polyclonal anti-FcRn followed by HSA-FITC at pH 7.4 and pH 5.5. The binding is 







                                                                               
                                                                                                                                   
  
4.5 Human hepatocytes express FcRn mRNA 
 
        Expression and diverse functions of FcRn in different tissues is continually reported. 
To contribute to the understanding of how the receptor functions according to cell type, 
we investigated the expression of FcRn in human hepatocytes.  
        To investigate whether human hepatocytic cell lines (Hep-3B and Hep-G2) express 
specific mRNA for the hFcRn heavy chain, RT-PCR was performed. The monocytic U-
937 cell line was used as a positive control in addition to the housekeeping gene GAPDH 
that was used as an internal control in all reactions. First, reverse transcriptions were done 
on total RNA from the cells using anchored Oligo (dT)20 primer which enable synthesis 
of full-length cDNA, followed by PCR with primers specific for heavy chain. The PCR 
products were run on an agarose gel, and as shown in figure 10A, fragments were 
obtained from both hepatic cell lines and they migrated as expected bands of 1098 bp. To 
determine whether the PCR products were indeed amplified hFcRn heavy chain, the 
bands were excised and purified for sequencing. The PCR products sequenced (Appendix 
B) were identical to the previously determined cDNA sequence of hFcRn (GeneBank, 
NM 004107; 7). Furthermore, the mRNA for β2m was reverse transcribed and PCR 
amplified (Fig. 10B). The amplified fragments migrated as bands corresponding to the 
expected size of 360 bp. These results showed that hFcRn transcripts were expressed in 
human hepatocytes. 
       The hFcRn heavy chain cDNA in pcDNA3-(TM-hFcRn)-GST.Pcmv-beta2m-polyA 
vector was subcloned into fluorescent protein vectors. To show whether the constructs 
are functional, MDCK cell line stably expressing hβ2m transiently transfected with 
vectors encoding fluorescent proteins in N-terminal fusion with hFcRn heavy chain 
cDNA. Analysis of these cells by confocal microscopy showed FcRn expression and its 
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    St.          1               2              3              
 
 Figure 10. Expression of the hFcRn heavy chain and hβ2m mRNA. RNA was 
reverse transcribed and PCRs were performed as described in material and methods. (A) 
The hFcRn heavy chain PCR products amplified from U-937 (Lane 1), Hep3B (Lane 2) 
and HepG2 (Lane 3). (B) The hβ2m PCR products from U-937 (Lane 1), Hep-3B (Lane 
2), Hep-G2 (Lane 3) and the pCDNA3-hβ2m vector (Lane 4). (C) The GAPDH PCR 
products amplified from U-937 (Lane 1), Hep-3B (Lane 2) and Hep-G2 (Lane 3). 
Amplified PCR products were run on 1 % agarose gel and stained with ethidium 
bromide. St. is standard molecular weight phixX174 DNA marker. The molecular sizes 
are indicated by arrows. 
 
 
4.6 Human hepatocytes express FcRn  
 
        Western immunoblotting was carried out on total lysates using the polyclonal anti-
hFcRn preparation. Figure 11A shows detection of bands corresponding to ~45 kDa in 
lysates from all cell lines. In addition, bands of ~12 kDa corresponding to hβ2m were 
detected. The protein bands are consistent with the calculated molecular weight of hFcRn 
heavy chain and hβ2m. ELISA analyses on total lysates also support the expression of 
both proteins (data not shown). Furthermore, Western immunoblotting of total protein 
isolated from human liver shows detectable expression of the both the hFcRn heavy chain 
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as well as the hβ2m subunit (Andersen et al; data not shown).  
 
 
       
       
   
ein lysates 
      Furthermore, flow cytometric analyses were performed to demonstrate surface 
  1          2   3         4  5            6 
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            12 kDa 
Figure 11. Expression of hFcRn. (A) Detection of hFcRn heavy chain in prot
from U-937 (Lane 1 and 2), Hep-3B (Lane 3 and 4) and Hep-G2 (Lane 5 and 6) cells by 
western immunoblotting. (B) Detection of hβ2m in protein lysates from U-937 (Lane 1), 
Hep-3B (Lane 2) and Hep-G2 (Lane 3) by western immunoblotting. Similar experiments 
repeated with identical results. 
 
  
expression of hFcRn using the goat anti-FcRn preparation. Figure 12 shows histograms 
for surface staining of Hep-3B (Fig. 12A) and Hep-G2 (Fig. 12B), and total hFcRn 
expression was verified after saponin treatment of Hep-3B (Fig. 12C) and Hep-G2 (Fig. 
12D). The presence of a shoulder seen for both hepatic cell lines at surface was detected 
in all experiments. The results clearly reveal the presence of the transmembrane hFcRn. 
Taken together, both FcRn subunits were shown to be expressed in the hepatic cell lines 
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.7 Functional FcRn is expressed in human hepatocytes  












Figure 12. Expression and cellular distribution of FcRn in human hepatocytes. Cells 
were stained with biotinylated anti-FcRn followed by streptavdin-FITC and analysed by 
flow cytometry. Hep-3B cells surface stained (A) and total (B). Hep-G2 cells surface 
stained (C) and total (D). FcRn expression is shown as gray filled histograms, 
streptavidin-FITC and isotype (biotinylated goat IgG) controls as gray lined histograms. 







dependent binding assay was established. Total protein lysates were immunoprecipitated 
using hIgG covalently coupled to Sepharose 4B. Binding experiments were performed at 
pH 5.5 as well as at pH 8.0, all as described in material and methods. Eluted fractions 
were applied to reducing SDS-PAGE analysis followed by Western immunoblotting. 
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Figure 13 shows that hFcRn binds IgG at pH 5.5 but not at pH 8.0. The major bands 
correspond to ~ 45 kDa, which is in agreement with the expected size of the hFcRn heavy 
chain. In addition, hβ2m was co-eluted and detected as a band of ~12 kDa. Taken 
together, the data show that hFcRn is expressed by the hepatocytes as a heterodimeric 
molecule and is to binds IgG at pH 5.5 but not at pH 8. The results confirm the results 
from are similar with previous work that describes pH dependent binding of IgG to a 
receptor in rat neonatal enterocytes (45).  
                       
 
 
 Detection of pH-dependent FcRn binding to hIgG. 400-600 µg of total 
-          +      -        +       -       + 
+         -       +       -        +      - 
pH 5.5 
pH 8.0 
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Figure 13.
proteins were incubated with human IgG coupled Sepharose at 4ºC at pH 5.5 or pH 8.0 as 
described in materials and methods. The eluted fractions were subjected to 12 % SDS-
PAGE under reducing conditions. U-937 fractions from experiments performed at pH 5.5 
(lane 1) and pH 8.0 (lane 2). Hep-3B fractions from experiments performed at pH 5.5 
(lane 3) and pH 8.0 (lane 4). Hep-G2 fractions from experiments performed at pH 5.5 
(lane 5) and pH 8.0 (lane 6). Proteins were probed with goat anti-hFcRn heavy chain and 
rabbit anti-hβ2m antibodies followed by HRP-conjugated secondary antibodies. The 






                                                                               




.8 Membrane-bound hFcRn binds both hIgG and HSA in a pH dependent manner 
   To explore IgG binding to surface expressed hFcRn, the expression profiles of 




classical Fcγ receptors had to be considered. Both hepatic cell lines were stained and data 
obtained showed expression of the low affinity binding FcγRII (CD32) but no evidence 
of FcγRI (CD64) and FcγRIII (CD16) expression (Fig.14).  
 
 




towards each Fcγ receptor as described in material and methods. Hep-3B cells surface 
stained for for FcγRI, FcγRII and FcγRIII (A, B and C). Hep-G2 cells surface stained for 
FcγRI, FcγRII and FcγRIII (D, E and F). Fcγ receptors are shown as gray filled 
histograms and controls (isotype and secondary antibodies) as unfilled histograms. 




cells were stained using hIgG-FITC followed by flow cytometry analyses. We found that 
Hep-3B showed increased binding of hIgG at pH 5.5 as compared to pH 7.4 (Fig.15A-B). 
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Figure 15. FcRn ligands binding to Hep3B cells. (A) Binding of hIgG-FITC, Fab2 and 
mIgG2a (A) to Hep3B cells at pH 5.5 and at pH 7.4. (B) Binding of HSA at pH 5.5 and 
pH 7.4. The binding is expressed as mean fluorescence intensity (MFI). The experiments 




and HSA. The results clearly demonstrate competitive binding by showing decreased 
binding of FITC conjugated ligands to Hep-3B (Fig.16A-B). Furthermore, cells were pre-
blocked with polyclonal anti-FcRn followed by staining with IgG-FITC and HSA-FITC. 
In addition, labelled hIgG pre-incubated with Streptococcus protein G resulted in reduced 
IgG-FITC binding, clearly demonstrating Fc mediating binding at pH 5.5 (Fig. 16A). 
Figure 15A-B shows that targeting of hFcRn with anti-FcRn inhibits functional binding 
of the ligands. Thus, the increased binding shown at acidic pH is related to specific FcRn 
binding. Similar results were obtained from experiments performed on the Hep-G2 cell 





                                                                               
                                                                                                                                   
  








Figure 16. hFcRn-ligand inhibition analysis on Hep-3B cells. (A) Hep-3B cells stained 
with IgG-FITC alone or stained after pre-incubation with polyclonal anti-FcRn or in 
presence of protein G. (B) Hep-3B cells stained with HSA-FITC alone or stained after 
pre-incubation with polyclonal anti-FcRn. The binding is expressed as mean fluorescence 
intensity (MFI). The experiments were repeated with similar results.  
                                             
        To determine whether IgG and HSA bind to membrane-bound hFcRn 
simultaneously, cells were stained with either IgG-FITC or HSA-FITC alone or 
simultaneously at pH 5.5. Figure 17 shows that double staining of Hep-3B resulted in an 






                                                                               






Figure 17. The hIgG and HSA bind to membrane bound hFcRn independently of 
each other. Hep-3B cells were surface stained with HSA-FITC and hIgG-FITC 
simultaneously. HSA-FITC, hIgG-FITC and together are shown as white, gray and black 
filled histograms, respectively. Histograms are given with ordinate indicating number of 
cells and abscissa indicating the fluorescence intensity. 
 
 
4.9 Anti-inflammatory substances modulate the expression of the hFcRn 
 
         Previous data have shown down regulation of rat FcRn three weeks postnatally (43, 
44). The molecular mechanism is not fully understood, but exposure to exogenous 
glucocorticoides and thyroxine hormone causes inhibition of transepitelial transport of 
orally administered IgG. These classes of substances are widely used as anti-
inflammatory agents in first-line therapy of persistent asthma, inflammatory and immune 
diseases (48). To assess whether glucocorticoides and L-thyroxine influence IgG transport 
by regulation of hFcRn expression, the monocytic U-937 cell line in addition to the 
hepatic cell lines (Hep-3B and Hep-G2) were treated with different naturally occurring 
hormones (corticosterone and L-thyroxine) as well as a synthetic version (prednisolone). 
Cells were given 0.010-1 μM of each substance and three days post treatment, and the 
hFcRn expression was assessed by flow cytometric analyses. The results clearly 
demonstrate decreased receptor surface expression on both U-937 (Fig. 18A) and Hep-3B 
(Fig. 18B) in a concentration dependent manner for all substances given, compared to 
untreated cells. In addition, two other clinically used anti-inflammatory synthetic versions 
(dexamethasone and beclomethasone dipropionate) were tested and shown to 
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downregulate hFcRn in a similar manner (data not shown). Similar results were also 
obtained with the Hep-G2 cell line (data not shown). Furthermore, the effect on total 
hFcRn expression was investigated using 1 μM of the given substance. Three days post 
treatment cells were permeablized followed by staining of hFcRn. The data obtained 
show a dramatic downregulation of receptor expression in U-937 (Fig. 18C) and Hep-3B 
(Fig. 18D) for all substances tested. These data may contribute to the clinical 
understanding of anti-inflammatory treatment, especially in regard to critical regulation 
of IgG and HSA homeostasis. 
 
 


















                                                                               
                                                                                                                                   
  




                                                                                                                                                                         
 





Figure 18. Effects of anti-inflammatory substances on FcRn expression. (A) FcRn 
surface expression in U-937 cells after treating with 0.01 μM, 0.1 μM, and 1.0 µM of L-
thyroxine (LT), corticosterone (CT) or predisolone (PD). (B) Total FcRn expression in U-
937 cells after treating with 1 µM L-thyroxine, corticosterone and predisolone. (C) FcRn 
surface expression in Hep-3B cells after treating with 0.01 μM, 0.1 μM, and 1.0 µM of L-
thyroxine (LT), corticosterone (CT) and predisolone (PD). (D) Total FcRn expression in 
Hep-3B cells after treating with 1 µM L-thyroxine, corticosterone and predisolone. The 
FcRn expression is shown as mean fluorescence intensity (MFI) three days post 
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5.  Discussion 
 
         Originally, FcRn was characterized functionally as the receptor that transfers IgG in 
the maternal milk from the intestine of neonatal rats to the blood stream. This is 
paralleled by transfer of IgG to fetus by transplacental transport in humans. Subsequent 
studies have revealed expression of the receptor and important functions beyond 
neonatal/fetal life in adult mammals including human. In this context, there is no report 
on FcRn expression and functions in human hepatocytes and limited data in immune 
cells. In this study, we have shown FcRn expression in three human monocytic U-937, 
THP-1 and K-562 cells, and PBMCs. Our studies, for the first time demonstrate that 
FcRn is expressed by human hepatic Hep-3B and Hep-G2 cells. We also found that the 
hepatic cells express FcγRII. Whether it is isoform A or B and its function remains be 
described. 
        It has been described that FcRn binds IgG in the slightly acidic pH of the intestinal 
lumen of neonatal rodent, and that IgG is released into the blood stream where the pH is 
basic (pH 7.4) (44). In our investigations, we found that binding of human monocytic cells 
and hepatocytes to hIgG and HSA display complete pH-dependence, showing increased 
binding at pH 5.5. In this study, we demonstrate that pre-incubation of cells with the 
polyclonal anti-FcRn preparation from goat blocked the binding of IgG as well as HSA 
observed at pH 5.5. This is important, because goat IgGs does not bind to human Fcγ 
receptors and hFcRn shows no binding to goat IgGs. Furthermore, irrelevant goat IgG did 
not affect the binding. Therefore, it can be concluded that the increased binding of hIgG 
and HSA to membrane-bound hFcRn is only due to FcRn. In light of these observations, 
the possibility of FcRn blockade by anti-FcRn has important therapeutic implications in 
humans. FcRn blockade by intravenous Ig (IVIG) significantly increases the catabolism 
of serum IgG in mice (45). Studies on the therapeutic effects of an anti-rat FcRn mAb, 
1G3, in two rat models of myasthenia gravis resulted in dose-dependent amelioration of 
the disease symptoms after passive experimental disease was induced by administration 
of an anti-acetylcholine receptor (AChR) mAb (46). The effect of 1G3 was also studied in 
an active model of experimental autoimmune myasthenia gravis in which rats were 
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immunized with AChR, and again treatment with 1G3 significantly reduced the severity 
of the disease symptoms as well as the levels of total IgG and anti-AChR IgG relative to 
untreated animals (46). 
        In addition, we report for the first time the pH dependent binding of HSA to 
membrane bound FcRn. Simultaneous staining of both ligands resulted in an additive 
binding effect compared with individual staining, which may indicate that both ligands 
bind independently to hFcRn. These data are in agreement with data obtained on 
biochemical studies performed on recombinant molecules (26, 28, 29).   
         In our studies, FcRn was found both intracellularly and on the cell surface of the 
monocytic cells, PBMCs and hepatocytes. The expression of FcRn on the surface may 
indicate a function of FcRn under physiological condition which involves delivery of IgG 
and HSA from the intracellular to extracellular milieu as protection from lysosomal 
degradation. Alternatively, the role of the surface FcRn may be in receptor mediated 
endocytosis, where FcRn may bind its ligands at acidic pH and the FcRn-ligand 
complexes delivered to acidic endosomal compartments in the cell. This is possible for 
FcRn expressed on the surface of immune cells and might have a role in pathological 
conditions such as tissue inflammation (33) and tumor infiltration (34, 35), where acidic 
extracellular conditions are created by alterations in tissue metabolism. The extracellular 
pH within solid tumors has been observed to be below physiological levels, ranging from 
5.6-7.7 (34) which includes the pH optimum of FcRn binding. Macrophages are recruited 
in the earliest phases of inflammatory condition such as inflammatory bowel disease (36) 
and they widely infiltrate to solid tumor tissues (37).  
        Where the pH outside the cell is neutral, IgG and HSA are initially internalized by 
endocytosis and FcRn binding occurs at low pH in intracellular compartments. Unbound 
IgG and HSA are delivered to the default lysosomal pathway and degraded. In contrast, 
the bound IgG and HSA to FcRn are protected and recycled back into surrounding tissue 
fluid. The fact that most of the receptor is found intracellularly, and that the steady state 
level of surface FcRn is very low suggests rapid recycling or that most of FcRn remain 
inside vesicles. Both immune cells and hepatocytes harbour Fcγ receptors for immune 
complexes, and these may deliver IgG to acidic compartments. Regarding albumin 
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uptake by receptor mediated mechanism, little is known about albumin receptors on such 
cells. None is characterized on immune cells, and a receptor for glutaraldehyde treated 
albumin is implicated in hepatitis B virus infection (38, 39, 40, 41). 
        FcRn was shown to be functionally expressed on the surface of adult rat hepatocytes 
and hypothesized to mediate transport of IgG from serum to bile (13). Rather, FcRn in 
hepatocytes has been implicated in protecting IgG from catabolism (32). Here, we confirm 
that the expression of FcRn by hepatocytes both on the surface and intracellularly may 
indicate a role in protection of IgG and HSA from catabolism and the maintenance of IgG 
and HSA levels in the blood. Therefore, the expression of FcRn on the cell surface of 
hepatocytes may reflect highly active sorting of IgG and HSA by FcRn from the 
endocytic pathway to the cell surface. Human hepatocytes have similar plasma fluid 
exposure as that of vascular endothelial cells which are the cells suggested protecting IgG 
from degradation (11). Histologically, human hepatocytes are in direct contact with huge 
amount of plasma fluid for the reason that separation from the blood stream is by 
discontinuous or fenestrated sinusoidal capillary that lack basement membrane. The 
human liver has two blood supplies and at any one time, as much as 10% of all the blood 
in the body is present in the liver. This anatomical context points to hepatocytes as the 
place where major catabolism of plasma proteins like IgG and albumin can occur. 
        Interestingly, both hepatocytes and hepatitis B virus bind albumin. Hepatitis B virus 
is known to infect hepatocytes and the infectivity of the virus is facilitated by the 
presence of surface antigen associated albumin binding protein. A receptor for 
glutaraldehyde treated albumin is found on hepatocytes (38, 39, 40, 41), and liver the only 
place where albumin biosynthesis takes place. Specific albumin receptors exist and are 
characterized as glycoproteins (42), however, its/their exact molecular identity remains to 
be elucidated. 
         Previous data on neonatal rats have shown downregulation of rat FcRn three weeks 
postnatal life (44). Exogenous glucocorticoids and thyroxine hormone have shown 
inhibition of transepithelial transport of orally administered IgG (43). Whether these 
effects are due to decreased FcRn expression has not thoroughly been investigated. 
        To address the question whether glucocorticoids, and L-thyroxine could influence 
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the hFcRn expression, the monocytic U-937 cells in addition to the hepatic Hep-3B and 
Hep-G2 cells were treated with different naturally occurring hormones (corticosterone 
and L-thyroxine) as well as a synthetic ones such as prednisolone, dexamethasone and 
beclomethasone dipropionate. The results clearly demonstrate decreased receptor 
expression on human U-937, Hep-3B and Hep-G2 cells in a concentration dependent 
manner for substances tested, compared to the untreated cells. In the present study, the 
sensitivity of the substances used and the time that needs to produce the effect were not 
considered. However, the results correlate well with clinical and experimental 
observations. Patients on glucocorticoid therapy often have decreased serum IgG 
concentration (49). This clinical observation has not been addressed in relation to factors 
that maintain IgG serum levels. Different factors may contribute to this observation but 
under the condition that FcRn expression is diminished, it is possible that IgG is neither 
transported nor protected from degradation. This is consistent with the previous report 
that hydrocortisone treatment results in hypogammaglobulinemia. The ability of 
glucocorticoids to decrease FcRn expression at the transcriptional level has been 
suggested (43) even though the exact mechanism is not understood. 
        Regarding HSA, there is no report on the correlation of glucocorticoids therapy and 
decreased serum concentration. But, we postulate that identical mechanism may operate 
given that FcRn binds in its function both to IgG and HSA in a similar fashion. 
        The levels of sensitivity, time period for action required, and the exact mechanisms 
involved in downregulation of FcRn expression and its correlation to reduced serum 
concentration of IgG and HSA need further investigation. 
         Such data may contribute to the clinical understanding of anti-inflammatory 
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 Appendix A.   
 
The functional integrity of FITC conjugated hIgG and HSA were tested by surface 
plasmon resonance.  
 
Recombinant shFcRn was immobilized on a CM5 sensor chip by amine coupling. IgG-
FITC and HSA-FITC were injected at pH 6.0 followed by injection of a buffer with pH 
7.4. Representative sensorgrams show that IgG-FITC (1) and HSA-FITC (2) bind FcRn 
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Sequence of transmembrane (TM) human FcRn isolated from the hepatic HepG2 
cell line: 
  
Template: pcDNA3-TM hFcRn-GST-Pcmv-β2m-polyA 
Primer: FcRn primer-2926 and GST-rev (custom designed by GATC) 
Total length: 1098 nucleotides 
 
GATC Gmbh, Germany, performed the sequencing reactions and the results are given 
below with CLUSTAL W (1.83) multiple sequence alignment. 
In the alignment: “Human” stands for the published cDNA sequence of hFcRn  
(GeneBank, NM 004107). The isolated TM hFcRn cDNA from HepG2 cells is aligned. 
The sequences are 100% identical. The start codons (ATG) are shown in bold and the 
stop codons (TGA) are underlined.  
  
Human       ATGGGGGTCCCGCGGCCTCAGCCCTGGGCGCTGGGGCTCC 40 
HepG2       ATGGGGGTCCCGCGGCCTCAGCCCTGGGCGCTGGGGCTCC 40                  
            **************************************** 
Human       TGCTCTTTCTCCTTCCTGGGAGCCTGGGCGCAGAAAGCCA 80                  
HepG2       TGCTCTTTCTCCTTCCTGGGAGCCTGGGCGCAGAAAGCCA 80                  
            ****************************************       
Human       CCTCTCCCTCCTGTACCACCTTACCGCGGTGTCCTCGCCT 120  
HepG2       CCTCTCCCTCCTGTACCACCTTACCGCGGTGTCCTCGCCT 120 
            **************************************** 
Human       GCCCCGGGGACTCCTGCCTTCTGGGTGTCCGGCTGGCTGG 160 
HepG2       GCCCCGGGGACTCCTGCCTTCTGGGTGTCCGGCTGGCTGG 160 
            ****************************************                     
Human       GCCCGCAGCAGTACCTGAGCTACAATAGCCTGCGGGGCGA 200 
HepG2       GCCCGCAGCAGTACCTGAGCTACAATAGCCTGCGGGGCGA 200 
            **************************************** 
Human       GGCGGAGCCCTGTGGAGCTTGGGTCTGGGAAAACCAGGTG 240 
HepG2       GGCGGAGCCCTGTGGAGCTTGGGTCTGGGAAAACCAGGTG 240 
            **************************************** 
Human       TCCTGGTATTGGGAGAAAGAGACCACAGATCTGAGGATCA 280 
HepG2       TCCTGGTATTGGGAGAAAGAGACCACAGATCTGAGGATCA 280 
            **************************************** 
Human       AGGAGAAGCTCTTTCTGGAAGCTTTCAAAGCTTTGGGGGG 320 
HepG2       AGGAGAAGCTCTTTCTGGAAGCTTTCAAAGCTTTGGGGGG 320 
            **************************************** 
Human       AAAAGGTCCCTACACTCTGCAGGGCCTGCTGGGCTGTGAA 360 
HepG2       AAAAGGTCCCTACACTCTGCAGGGCCTGCTGGGCTGTGAA 360 
            **************************************** 
Human       CTGGGCCCTGACAACACCTCGGTGCCCACCGCCAAGTTCG 400 
HepG2       CTGGGCCCTGACAACACCTCGGTGCCCACCGCCAAGTTCG 400 
            **************************************** 
Human       CCTGAACGGCGAGGAGTTCCATGAATTTCGACCTCAAGCA 440 
HepG2       CCTGAACGGCGAGGAGTTCCATGAATTTCGACCTCAAGCA 440 
            **************************************** 
98 
  
                                                                               




Human       GGGCACCTGGGGTGGGGACTGGCCCGAGGCCCTGGCTATC 480 
HepG2       GGGCACCTGGGGTGGGGACTGGCCCGAGGCCCTGGCTATC 480  
            **************************************** 
Human       AGTCAGCGGTGGCAGCAGCAGGACAAGGCGGCCAACAAGG 520 
HepG2       AGTCAGCGGTGGCAGCAGCAGGACAAGGCGGCCAACAAGG 520 
            **************************************** 
Human       AGCTCACCTTCCTGCTATTCTCCTGCCCGCACCGCCTGCG 560 
HepG2       AGCTCACCTTCCTGCTATTCTCCTGCCCGCACCGCCTGCG 560 
            **************************************** 
Human       GGAGCACCTGGAGAGGGGCCGCGGAAACCTGGAGTGGAAG 600 
HepG2       GGAGCACCTGGAGAGGGGCCGCGGAAACCTGGAGTGGAAG 600 
            ****************************************                       
Human       GAGCCCCCCTCCATGCGCCTGAAGGCCCGACCCAGCAGCC 640 
HepG2       GAGCCCCCCTCCATGCGCCTGAAGGCCCGACCCAGCAGCC 640 
            **************************************** 
Human       CTGGCTTTTCCGTGCTTACCTGCAGCGCCTTCTCCTTCTA 680  
HepG2       CTGGCTTTTCCGTGCTTACCTGCAGCGCCTTCTCCTTCTA 680 
            **************************************** 
Human       CCCTCCGGAGCTGCAACTTCGGTTCCTGCGGAATGGGCTG 720 
HepG2       CCCTCCGGAGCTGCAACTTCGGTTCCTGCGGAATGGGCTG 720 
            **************************************** 
Human       GCCGCTGGCACCGGCCAGGGTGACTTCGGCCCCAACAGTG 760 
HepG2       GCCGCTGGCACCGGCCAGGGTGACTTCGGCCCCAACAGTG 760 
            **************************************** 
Human       ACGGATCCTTCCACGCCTCGTCGTCACTAACAGTCAAAAG 800 
HepG2       ACGGATCCTTCCACGCCTCGTCGTCACTAACAGTCAAAAG 800 
            **************************************** 
Human       TGGCGATGAGCACCACTACTGCTGCATTGTGCAGCACGCG 840 
HepG2       TGGCGATGAGCACCACTACTGCTGCATTGTGCAGCACGCG 840 
            ****************************************                 
Human       GGGCTGGCGCAGCCCCTCAGGGTGGAGCTGGAATCTCCAG 880 
HepG2       GGGCTGGCGCAGCCCCTCAGGGTGGAGCTGGAATCTCCAG 880 
            **************************************** 
Human       CCAAGTCCTCCGTGCTCGTGGTGGGAATCGTCATCGGTGT 920 
HepG2       CCAAGTCCTCCGTGCTCGTGGTGGGAATCGTCATCGGTGT 920 
            **************************************** 
Human       CTTGCTACTCACGGCAGCGGCTGTAGGAGGAGCTCTGTTG 960 
HepG2       CTTGCTACTCACGGCAGCGGCTGTAGGAGGAGCTCTGTTG 960 
            ****************************************                
Human       TGGAGAAGGATGAGGAGTGGGCTGCCAGCCCCTTGGATCT 1000 
HepG2       TGGAGAAGGATGAGGAGTGGGCTGCCAGCCCCTTGGATCT 1000 
            **************************************** 
Human       CCCTTCGTGGAGACGACACCGGGGTCCTCCTGCCCACCCC 1040 
HepG2       CCCTTCGTGGAGACGACACCGGGGTCCTCCTGCCCACCCC 1040 
            **************************************** 
Human       AGGGGAGGCCCAGGATGCTGATTTGAAGGATGTAAATGTG 1080 
HepG2       AGGGGAGGCCCAGGATGCTGATTTGAAGGATGTAAATGTG 1080 
            ****************************************  
Human       ATTCCAGCCACCGCCTGA 1098  
HepG2       ATTCCAGCCACCGCCTGA 1098 
            ******************  
 
 
                
99 
  
                                                                               
                                                                                                                                   
  
 Appendix C. 
 Transient transfection of MDCK cells expressing hβ2m with fluorescent protein 
vectors.  
 
The MDCK cell line stably expressing hβ2m was transiently transfected with vectors 
encoding fluorescent proteins in N-terminal fusion with the hFcRn heavy chain 
cDNA. The cells were examined with confocal microscope. 
 
1. pEGFP-N1-TM hFcRn is transmembrane human FcRn in N-terminal fusion with 
green fluorescent protein (GFP) gene in pEGFP-N1 vector. Deep green staining 
shows FcRn distribution in edosomal compartments. 
2. pREP-N1-TM hFcRn is transmembrane human FcRn in N-terminal fusion with 
red fluorescent protein (RFP) gene in pRFP-N1 vector. Deep red staining shows 
FcRn distribution in endosomal compartments. 
 
     Nucleus/DNA was stained blue with Hoechst 
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